# Safety Assessment of PEG Diesters as Used in Cosmetics

Status: Release Date: Panel Meeting Date: Final Amended Report April 7, 2015 March 16-17, 2015

The 2015 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This report was prepared by Lillian C. Becker, Scientific Analyst/Writer.

© Cosmetic Ingredient Review

1620 L Street, NW, Suite 1200 ∀ Washington, DC 20036-4702 ∀ ph 202.331.0651 ∀ fax 202.331.0088 ∀ cirinfo@cir-safety.org

## ABSTRACT

This is a safety assessment of 55 polyethylene glycol (PEG) diesters as used in cosmetics. These ingredients mostly function in cosmetics as surfactants. The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) reviewed relevant data related to these ingredients. The similar structure, properties, functions and uses of these ingredients enabled grouping them and using the available toxicological data to assess the safety of the entire group. Much of the information for these ingredients consists of data on the PEG component and the various fatty acids that make up these ingredients. The Panel concluded that these PEG diesters are safe in cosmetics when formulated to be non-irritating. This conclusion supersedes the conclusion reached in the 3 former safety assessments.

## **INTRODUCTION**

This is a safety assessment of 55 PEG diesters as used in cosmetics. These ingredients are diesters of various fatty acids with the common core of the PEG moiety. These ingredients mostly function in cosmetics as surfactants (Table 1).<sup>1</sup>

In 1999, the Panel published a safety assessment of PEG distearates with the conclusion of safe as used (Table 2).<sup>2</sup> Because they are similarly structured fatty acid diesters with a PEG core, PEG dilaurates and other similar ingredients are included in this safety assessment. In 2000, a safety assessment of PEG dilaurates (which also included PEG laurates) was published with the conclusion of safe for use in cosmetics at concentrations up to 25%.<sup>3</sup> In 2011, a safety assessment of pelargonic acid-related ingredients, which included PEG-2 diisononanoate, was published with a conclusion of safe in the present practices of use and concentration.<sup>4</sup> Because there were little data available on the individual ingredients in these safety assessments, the Panel relied on read across and information on the moieties of these ingredients. Summaries of the reports on PEG distearate and PEG dilaurates are provided below; only new data are reported in the body of this safety assessment.

PEG-50 distearate, which was included in the original (1999) safety assessment, was not listed in the *International Cosmetic Ingredient Dictionary and Handbook*<sup>5</sup> (INCI) and is not currently listed as a cosmetic ingredient in the current edition.<sup>1</sup> Since this compound has a reported use in the Food and Drug Administration's (FDA) Voluntary Cosmetic Registration Program (VCRP), it is included in this safety assessment.

The following previously unreviewed PEG diesters have been added to this safety assessment because of similarities in chemical structure and cosmetic function to the previously reviewed PEG diesters:

PEG-40 distearate	PEG-175 diisostearate
PEG-190 distearate	PEG-2 dioleate
PEG-250 distearate	PEG-3 dioleate
PEG-150 dibehenate	PEG-4 dioleate
PEG-3 dicaprylate/caprate	PEG-6 dioleate
PEG-4 dicocoate	PEG-8 dioleate
PEG-8 dicocoate	PEG-10 dioleate
PEG-4 diheptanoate	PEG-12 dioleate
PEG-2 diisostearate	PEG-20 dioleate
PEG-3 diisostearate	PEG-32 dioleate
PEG-4 diisostearate	PEG-75 dioleate
PEG-6 diisostearate	PEG-150 dioleate
PEG-8 diisostearate	PEG-3 dipalmitate
PEG-12 diisostearate	PEG-8 ditallate
PEG-90 diisostearate	PEG-12 ditallate

CIR has conducted safety assessments of the acids and related moieties of these PEG diester ingredients (Table 2). The Panel concluded that coconut acid, isostearic acid, oleic acid, lauric acid, stearic acid, PEG stearates (PEG monoesters), stearates, and tall oil acid were safe as used.<sup>6-18</sup> The Panel concluded that steareths (PEG ethers) were safe as used when formulated to be nonirritating.<sup>19-21</sup>

#### SUMMARIES OF ORIGINAL REPORTS

## PEG Distearates

PEG-2,-3,-4,-6,-8,-9,-12,-20,-32,-50,-75,-120,-150, and -175 Distearate are the polyethylene glycol diesters of Stearic Acid.<sup>2</sup> These ingredients are surfactants that function as emulsifying, cleansing, and solubilizing agents in cosmetics. Product formulation data submitted to the Food and Drug Administration (FDA) indicate that PEG-2, -3, -4, -6,-8, -12, -50, and -150 Distearate were in use, and that they were used in 283 cosmetic formulations.

Because few data on the PEGs Distearate regarding metabolism, toxicity, mutagenicity, carcinogenicity, and clinical safety were available, this review presented data on the PEGs, Stearic Acid, Steareths, and the PEGs Stearate separately, as these data were considered applicable to the safety evaluation of the PEGs Distearate.

PEG Distearate absorption and metabolism data were not available. PEG absorption is related to molecular weight. Lower molecular weight PEGs are readily absorbed through damaged skin. Oral and intravenous studies on PEGs indicate that these substances are excreted, unchanged, in the urine and feces. In general, fatty acids (such as Stearic Acid) are readily absorbed and distributed to the tissues in humans. Fatty acids can traverse the placental barrier.

Toxicity data for the PEGs Distearate were not available. The PEGs Stearate, and Steareths had low oral toxicity in acute, short-term, subchronic and chronic studies. PEGs in general have a low oral and dermal toxicity; the larger molecular weight PEGs appear to be less toxic than the smaller PEGs in oral studies. The acute toxicity of cosmetic formulations containing up to 13% Stearic Acid was low. In subchronic and chronic feeding studies using rats the effects were more severe.

PEG Stearates were slightly irritating at undiluted concentrations in test animals. PEGs were nonirritating to the skin of rabbits and guinea pigs, and PEG-75 was not a sensitizer. Stearic Acid irritation ranged from moderate to no reaction. Cosmetic product formulations containing 1.0% Stearic Acid were weak, grade I sensitizers. Primary irritation and sensitization studies involving Stearic Acid and the PEGs Stearate were negative. Minimal ocular irritation occurred in tests with the PEGs, Stearic Acid, Steareths, and PEGs Stearate.

Although monoalkyl ethers of ethylene glycol are reproductive toxins and teratogenic agents, it was considered unlikely that the PEGs Distearate would cause reproductive or developmental effects based on their structural characteristics. In subchronic and chronic feed studies, PEG-6 [through]32 and PEG-75 did not induce adverse reproductive effects in rats. In a multigenerational study lasting 2 years, feed containing 10-20% PEG-8 Stearate or PEG-40 Stearate was fed to rats; the rats fed the diet had decreased offspring survival time, reproductive performance, and lactation efficiency, as well as increased offspring mortality. Neither PEG-8 Stearate nor PEG-40 Stearate at a dietary concentration of 5% affected reproductive success.

In mutagenicity studies, PEG-8 was negative in the Chinese hamster ovary cell mutation test and the sister chromatid exchange test. At concentrations up to 150 g/l, PEG-150 was not mutagenic in the mouse lymphoma forward mutation assay. Stearic Acid was not mutagenic in the Ames test. PEG-8 was not carcinogenic when administered orally, intraperitoneally, or subcutaneously to rodents. A low incidence of carcinomas, sarcomas, and lymphomas was evident in mice receiving multiple subcutaneous injections of Stearic Acid.

In clinical studies, PEG-8 was a mild sensitizer and irritant. Contact dermatitis and systemic toxicity in burn patients were attributed to a PEG-based topical ointment. The Steareths, PEGs Stearate, and Stearic Acid were not irritants, sensitizers, or phototoxins. Formulations containing Stearic Acid were not photosensitizing.

## **PEG Dilaurates**

The PEGs Dilaurate, PEGs Laurate, and PEG-2 Laurate SE are PEG diesters or esters of lauric acid that function as surfactants in cosmetic formulations.<sup>3</sup> In 1997, PEG-8 Dilaurate and PEG-12 Dilaurate were used in 40 cosmetic formulations, and PEG-2, -4, -8, -10, -15, and -200 Laurate were used in 20 formulations. The remaining ingredients from this family had no reports of use. In 1984, data submitted to the FDA indicated that the PEGs Dilaurate and PEGs Laurate were used at concentrations up to 25%.

The CIR Expert Panel has previously reviewed the safety in cosmetics of the PEGs Stearate, PEGs Distearate, PEGs, Laureths, and Lauric Acid. Based on the similarity in chemical structures, data from those evaluations have been used as a further basis for the safety assessment of the PEGs Dilaurate and PEGs Laurate in cosmetics.

These polyoxyethylene ester surfactants and emulsifiers are produced by the ethoxylation of fatty acids during uncatalyzed or alkali-catalyzed reactions. PEG-2 Laurate has been produced by the interesterification of coconut oil with diethylene glycol. PEG-n Laurate could contain unspecified amounts of the lauric acid diester of PEG and unreacted PEG. PEG-6 may contain small, unquantified amounts of monomer and dimers, and samples PEG-32 and PEG-75 contained peroxides as a result of autoxidation. In general, ethoxylated surfactants can contain 1,4-dioxane, a by-product of ethoxylation, which is then removed during purification of the finished products. Traces of the reactants, stearic acid, ethylene oxide, and the catalysts used could remain in the finished product.

Data on the absorption, metabolism, distribution, and excretion of the PEGs Dilaurate and PEGs Laurate were not available. PEG-40 Stearate was hydrolyzed in vitro by pancreatic lipase. In metabolism studies with rats, rabbits, dogs, and humans, the lower-molecular-weight PEGs were absorbed by the digestive tract and excreted in the urine and feces. The PEGs were readily absorbed through damaged skin.

Fatty acids such as Lauric Acid are absorbed, digested, and transported in animals and humans. During labeling studies, radioactivity was found in various tissues, blood, and lymph after oral, IV, IP, and intraduodenal administration of labelled fatty acids. The fatty acids can undergo  $\beta$ -oxidation to yield acetyl-CoA. Placental transfer of the fatty acids has been observed. Lauric Acid is transported via the lymph and portal systems; fatty acids are typically transported esterified to glycerol in chylomicrons and very-low-density lipoproteins.

The acute oral  $LD_{50}$  of PEG-12 Laurate was >25 g/kg in Harlan mice. In the same study, the IV  $LD_{50}$  was 500 mg/kg. During short-term feeding studies using chicks, concentrations of up to 2% PEG-4 or-8 Laurate did not cause adverse effects. Rats fed a diet containing 15.9 g/kg/day of 25% PEG-20 Laurate had diarrhea, inflammation of the anal

region, and blood clots in the anorectal region after 59 days of treatment. In a 70-day study, rats given 5% to 25% PEG-20 Laurate had diarrhea and inflammation of the anal region. The ingredient was irritating to the gastrointestinal tract, but not necrotizing, and monocyte/macrophage hyperplasia and splenic giant cells were noted more frequently in rats of the treated group than rats of the control group. In a chronic oral toxicity study, nine rats were fed 6% PEG-8 Dilaurate for 505 days. Four of the rats in each of the treatment and control groups died. Of the rats given PEG-8 Dilaurate, one had cystic spots on the liver, one had hemorrhagic lungs, and one had a large fibrosarcoma. In microscopic examinations, three rats had focal parenchymal hepatitis. Of the rats of the control group, four had hemorrhagic and congested lungs, one had hypertrophied testes, one had a concretion in the urinary bladder, two had cystic kidneys, and two had hepatic parasites. In microscopic examinations, one control rat had adrenal cortical hyperplasia, two had chronic interstitial nephritis of the kidneys, two had splenic lymphoid hyperplasia, one had focal parenchymal hepatitis, and one had hepatic vacuolization. During another feeding study, rats fed up to 25% PEG-20 Laurate for 2 years had hepatic cysts, cecal enlargement, slight gastric mucosal hyperplasia, and slight squamous epithelial hyperplasia. PEG-12 Laurate at a concentration of 1% did not cause ocular irritation in rabbits.

The IV  $LD_{50}$  values in Harlan mice for PEG-8 and -20 Distearate were 365 mg/kg and 220 mg/kg, respectively. The oral  $LD_{50}$  values of PEG-2-150 Stearate ranged from >10 g/kg to 32 g/kg in rats. The IP  $LD_{50}$  of PEG-8 Stearate in rats was >9 ml/kg. No signs of toxicity were observed when rats were given IP injections of 2.5 g/kg PEG-50 or -100 Stearate. A hair cream containing 1.5% PEG-6 Stearate had an oral  $LD_{50}$  of >34.6 g/kg. The acute dermal  $LD_{50}$  of 15% PEG-8 Stearate in rabbits was >10 ml/kg; the only effect noted was erythema at the application site at 24 hours. The PEGs Stearate caused only slight skin irritation and minimal ocular irritation when tested at concentrations of 100% in animals. PEG-8, -40, and -100 Stearate did not cause significant changes in growth mortality rates, microscopic observations, or hematological values during long-term feeding studies. In clinical studies, the PEGs Stearate were not irritating or sensitizing when tested at concentrations of 25%. In addition, they did not cause photosensitization. PEG-8 and -40 Stearate did not cause reproductive or developmental effects, and were noncarcinogenic.

In acute toxicity studies, the PEGs had low oral and dermal toxicity. The PEGs were not irritating to the skin of rabbits or guinea pigs, and minimally irritating to the skin of humans. They did not cause sensitization in animal or human studies using intact skin, but sensitization and nephrotoxicity were observed in bum patients that were treated with a PEG-based cream. PEG was determined to be the causative agent in both animal and human studies. In ocular irritation studies, the PEGs caused mild, transient ocular irritation in rabbits. Cosmetic product formulations containing up to 13% Lauric Acid did not cause primary or cumulative irritation and did not cause sensitization.

The available data indicated that the PEGs were not mutagenic or carcinogenic.

A product formulation containing 5% Lauric Acid was nontoxic to rats during an oral toxicity study. Transient signs of toxicity (mucoid diarrhea, depression, unkempt fur, etc.) were observed when male rats were fed 0.46 to 10 g/kg Lauric Acid. In this study, one rat died; it had congested lungs and kidneys, and advanced autolytic changes. In a subchronic oral toxicity study, rats fed 10% Lauric Acid had no signs of toxicity. Lauric Acid was also noncarcinogenic in animal tests. It is generally recognized that the PEG monomer, ethylene glycol, and certain of its monoalkyl ethers are reproductive and developmental toxins. The PEGs Dilaurate and PEGs Laurate are diesters and esters of PEG and, as such, are chemically different from PEG alkyl ethers. Hence, they are not expected to cause adverse reproductive or developmental effects.

#### **CHEMISTRY**

## **Definition and Structure**

The ingredients in this report are the PEG diesters of various acids (eg, stearic acid, lauric acid, oleic acid). The different chain lengths of the PEGs are formed by condensing ethylene oxide and water. The average number of ethylene oxide repeat units per polyethylene glycol chain correspond to the number in the name (eg, PEG-4 diheptanoate is prepared from a polyethylene glycol chain, that is 4 ethylene oxide repeated units long on average, esterified on both ends of the chain with heptanoic acid).<sup>17</sup>

PEG-8 ditallate and PEG-12 ditallate are the diesters of the corresponding PEGs and tall oil acid. The composition of tall oil acid varied with the source pine tree species, climate, and other growing conditions.<sup>22</sup> For example, one source reported the composition to consist of oleic acid (48%), linoleic acid (35%), conjugated linoleic acid (7%), stearic acid (2%), palmitic acid (1%), other acids (4%), and unsaponifiable matter (2%).

#### **Physical and Chemical Properties**

The PEG distearates have a broad range of properties depending on the degree of polymerization of the PEG segment.<sup>23</sup> The physical forms of these ingredients range from liquids to solids. Solubility is also dependent on the length of the PEG component. Typically, these ingredients are soluble in oil and hydrocarbon solvents when less than 8 ethylene oxide units are present. Ingredients with short polyethylene glycol components in this group are insoluble in water. Solubility in water begins with compounds containing 12-15 ethylene oxide units and increases proportionally the longer the PEG chain gets. For example, PEG-2 dilaurate and PEG-4 dilaurate are dispersible in water while PEG-150 dilaurate is soluble in water.<sup>24</sup> Specific gravity and viscosity increase with increasing ethylene oxide repeat units.<sup>23</sup> As a representative example, though, PEG-4 diheptanoate was reported to be a clear liquid with a boiling point of >300°C, a specific gravity of 0.996, and

a vapor pressure of <0.1 mmHg at 37°C.<sup>25</sup> It is soluble in alcohol, acetone, and most organic solvents. PEG-150 dilaurate is a tan, waxy solid with a slight fatty odor.<sup>24</sup> The melting range is 53-60°C and it is soluble in isopropanol, toluene, and water (Table 3).

### **Method of Manufacture**

In general, the PEGs diesters are manufactured by the esterification of an acid with ethylene oxide or with a polyethylene glycol.<sup>26</sup>

## Impurities

Traces of the reactants, stearic acid, ethylene oxide, and the catalytic agents used, may remain in the finished product.<sup>17</sup>

PEG-150 distearate was reported to contain peroxide concentrations of 1.97 and 1.92  $\mu$ Eq thiosulfate/g glycol.<sup>27</sup> PEGs may contain small amounts of monomer and dimers, as well as peroxides.<sup>28</sup> Peroxide in PEGs is dependent upon the molecular weight of the PEG and its age.<sup>27</sup>

Because PEGs may contain trace amounts of 1,4-dioxane, a by-product of ethoxylation, this impurity may be present in PEG diesters.<sup>29</sup> 1,4-Dioxane is a known animal carcinogen.<sup>30</sup> Commercial grade triethylene glycol has been found to contain <1 ppm dioxane.<sup>31</sup> The cosmetic industry reported that it is aware that 1,4-dioxane may be an impurity in PEGs and, thus, uses additional purification steps to limit it in these ingredients before blending into cosmetic formulations.<sup>17</sup>

PEG-4 diheptanoate was reported to be 88% pure; the remaining substance consisted of triethylene glycol di-*n*-heptanoate (6%), mixed ester of tetraethylene glycol with *n*-heptanoic and 2-methylhexanoic acids (4%), and other mixed esters (2%).<sup>25</sup>

It was reported that PEGs may contain small amounts of ethylene oxide monomer and dimers.<sup>32</sup> The amounts were not quantified.

## <u>USE</u>

## Cosmetic

The Panel assesses the safety of cosmetic ingredients based on the expected use of these ingredients in cosmetics. The Panel reviews data received from the FDA and the cosmetics industry to determine the expected cosmetic use. The data received from the FDA are collected from manufacturers on the use of individual ingredients in cosmetics, by cosmetic product category, through the FDA VCRP, and the data from the cosmetic industry are submitted in response to a survey of the maximum reported use concentrations, by category, conducted by the Personal Care Products Council (Council).

Of the ingredients in this safety assessment, PEG-150 distearate was reported to have the highest number of uses at 690 in 2015 (an increase from 187 in 1996).<sup>2,33,34</sup> Most of these uses are in bath and personal cleansing products and shampoos. The rest of the ingredients are reported to have 48 or fewer uses (Tables 4, 5).

PEG-50 distearate, which was included in the original safety assessment, was not then and is not currently listed in the INCI Dictionary.<sup>1</sup> However, the VCRP has 1 reported use in a cleansing product.<sup>33</sup> In 1996, it was used in 1 cleansing preparation.<sup>2</sup>

A survey was conducted by the Personal Care Products Council (Council) of the maximum use concentrations for each ingredient in this group.<sup>35</sup> PEG-150 distearate was reported to have the highest concentration of use at up to 33.2% (an increase from 5% in 1995).<sup>2,35</sup> PEG-150 distearate is reported to be used in a rinse-off baby product up to 9.4%, bath products up to 4.5%, and in skin cleansing products up to 33.2%. PEG-4 dilaurate and PEG-8 dilaurate were reported to be used up to 25% in 1984, and are currently used up to 12% and 15%, respectively.<sup>3</sup> The rest of the ingredients were reported to be used at 15% or less (Tables 4, 5). Table 6 lists the 32 ingredients that have no reported uses according to the VCRP and the Council survey.

In some cases, the VCRP reported uses but no concentration-of-use data were available. For example, PEG-120 distearate is reported to be used in 7 formulations, but no use concentration data were available. In other cases, no reported uses were received in the VCRP, but a use concentration was provided in the industry survey. For example, PEG-175 distearate was not reported in the VCRP to be in use, but the industry survey indicated that it is used in shaving cream formulations at up to 0.089%. It should be presumed that PEG-175 distearate is used in at least one cosmetic formulation.

PEG-12 dioleate was reported to be used in pump hair sprays up to 0.024% and PEG-4 dilaurate was reported to be used in pump spray suntan products at 0.072%; these products could possibly be inhaled. In practice, 95% to 99% of the droplets/particles released from cosmetic sprays have aerodynamic equivalent diameters >10  $\mu$ m, with propellant sprays yielding a greater fraction of droplets/particles below 10  $\mu$ m compared with pump sprays.<sup>36-39</sup> Therefore, most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and bronchial regions and would not be respirable (ie, they would not enter the lungs) to any appreciable amount.<sup>36,38</sup>

All of the PEG diesters named in the report, with the exception of PEG-3 dicaprylate/caprate, PEG-4 diheptanoate, and PEG-50 distearate, are not restricted from use under the rules governing cosmetic products in the European Union.<sup>40</sup> PEG-3 dicaprylate/caprate, PEG-4 diheptanoate, and PEG-50 distearate are not listed in the European Union CosIng database.

#### Non-Cosmetic

Several of the PEG diesters may be used as defoaming agents in foods, as indirect food additives in paperboard products, in food contact surfaces, and as additives in animal feed and drinking water (Table 7).

### **TOXICOKINETICS**

#### **Dermal Penetration Enhancement**

Neither PEG-8 dioleate (5% w/w) nor PEG-8 dilaurate (5% w/w) enhanced the dermal penetration of ketoprofen through full-thickness CD-1 nude mouse skin when added to a drug delivery plaster preparation.<sup>41</sup> PEG-12 dioleate (5%) did enhance the dermal penetration of ketoprofen with an enhancement ratio (ER) of  $1.54\pm0.22$ . The study was conducted using Franz cells; the receptor cell was filled with freshly prepared degassed pH 7.4 phosphate-buffered saline. The samples were taken from the receptor cell and analyzed by high-performance liquid chromatography (HPLC) at 1, 2, 4, 8, and 24 h.

## TOXICOLOGICAL STUDIES

Acute Toxicity

## Oral – Non-Human

#### **PEG-4 DIHEPTANOATE**

The oral  $LD_{50}$  values reported for PEG-4 diheptanoate in rats ranged from >2->25 g/kg (Table 8).<sup>25, 42</sup> Clinical signs included labored breathing, belly-to-cage posture, lacrimation, staining of the face, stained and wet perineal area, and weight loss.

#### Inhalation – Non-Human

## **PEG-4 DIHEPTANOATE**

All the Crl:CD rats (n=6) exposed to vaporized (by applying heat, not aerosolized) PEG-4 diheptanoate (14.2 mg/L) for 4 h died during the exposures; all rats (n=6) exposed to 13.7 mg/L or less survived.<sup>25</sup> At all concentrations (2.1-14.2 mg/L), the clinical signs included salivation, red nasal discharge, and irregular respiration during the exposure period. The rats recovered quickly during the recovery period. Lethargy was observed starting at a concentration of 12.7 mg/L or greater. Rats exposed to 13.7 mg/L showed moderate weight loss (approximately 10% of initial body weight) the first 3-4 days post-exposure. The rats with weight loss also presented an unthrifty appearance with staining of the perineal area prominent during the first week of the 14-day recovery period.

## **Repeated Dose Toxicity**

#### Oral – Non-Human

#### **PEG-4 DIHEPTANOATE**

There were no adverse effects observed when PEG-4 diheptanoate (1 g/kg in corn oil) was administered by gavage to Crl:CD rats (10/sex) for 28 consecutive days.<sup>25</sup> Pathologic examinations at the end of the test period and after the 14-day recovery period were unremarkable.

#### Inhalation – Non-Human

#### **PEG-4 DIHEPTANOATE**

Following the repeated inhalation exposure of vaporized (by applying heat, not aerosolized) PEG-4 diheptanoate (1.0 mg/L) for 6 h/day, 5 days/week for 4 weeks, clinical signs for CrI:CD rats (n=10) were mild salivation, reduced response to auditory stimulation, and shallow and rapid respiration sporadically during the exposure periods.<sup>25</sup> The clinical signs were absent when the rats were not being exposed and during the 14-day recovery period. A trace of lung noise and brown staining of the nose were observed in 1 of the treated rats during recovery. Body weight changes were similar to the controls. Gross pathologic evaluation was unremarkable. Histopathologic examination of tissues found no lesions attributable to the test substance.

#### REPRODUCTIVE AND DEVELOPMENTAL TOXICITY

New data on the reproductive and developmental toxicity of PEG diesters were not found in the published literature, nor were unpublished data provided.

### **GENOTOXICITY**

#### **PEG-4 DIHEPTANOATE**

PEG-4 diheptanoate was not mutagenic at up to 10 000  $\mu$ g/plate in a reverse mutation assay using *Salmonella typhimurium* (strains TA98, TA100, TA1535, TA1537) or at up to 23.9 mM in a mammalian cell gene mutation assay using Chinese hamster ovary cells (Table 9).<sup>42</sup>

## **CARCINOGENICITY**

New data on the carcinogenicity of PEG diesters were not found in the published literature, nor were unpublished data provided.

## IRRITATION AND SENSITIZATION Irritation

#### Dermal – Non-Human

#### PEG-4 DIHEPTANOATE

PEG-4 diheptanoate (100%; 0.5 mL) caused slight (1), mild (3), or no (2) erythema to the skin of New Zealand White rabbits (n=6) when administered to the skin for 24 h.<sup>25</sup> At the removal of the test material, there was no edema observed on any of the rabbits. At 24 h after removal, there was little change in the erythema responses and edema (moderate in 1 rabbit; mild in 2 rabbits, and absent in 3 rabbits).

There was no skin irritation observed in a preliminary study using male BC/DHA guinea pigs (n=3) treated with PEG-4 diheptanoate (5% or 25%; 0.05 mL in dimethyl phthalate).<sup>25</sup> At a concentration of 50%, mild irritation in 1 guinea pig was observed, and at 100% there was mild irritation on all 3 guinea pigs.

## Ocular

#### PEG-4 DIHEPTANOATE

There were no lasting reactions observed when PEG-4 diheptanoate (100%; 0.1 mL) was instilled in the conjunctival sac of New Zealand White rabbits (n=2).<sup>25</sup> The cornea, iris, and conjunctiva of 1 rabbit (the treated eye of this rabbit remained unwashed following administration) showed no adverse effects. The eye of the other rabbit (the treated eye of this rabbit was washed with copious amounts of water 20 seconds after administration) showed slight conjunctival swelling which lasted for 4 h. The swelling was resolved at 24 h. No changes in the corneal or iritic tissues were observed.

#### Sensitization

## Dermal – Non-Human

#### **PEG-4 DIHEPTANOATE**

In a dermal sensitization study using male BC/DHA guinea pigs (n=10), PEG-4 diheptanoate (5% or 25%; 0.05 mL in dimethyl phthalate) was not sensitizing when challenged at 5% or 50%.<sup>25</sup> The test substance was administered to the shaved skin of the shoulder of the guinea pigs followed 2 days later by an injection of dimethyl phthalate (1%; 0.1 mL). Three more injections, 1 week apart, were administered to complete the induction phase. After a 13-day rest period, the challenge was administered as a topical administration of PEG-4 diheptanoate (5% or 50% in dimethyl phthalate; 0.05 mL) to the same shaven shoulder. The control consisted of a group of naïve guinea pigs (n=10) that were administered the challenge.

#### **SUMMARY**

This is a safety assessment of PEG diesters as used in cosmetics. These ingredients are diesters of various fatty acids with the common core of the PEG moiety and mostly function in cosmetics as surfactants. Several of these ingredients have been reviewed by the Panel previously and the data in those safety assessments were considered along with the new data presented here.

In previous safety assessments, it was concluded that several PEG distearates were safe as used in cosmetics and several PEG dilaurates were safe up to 25%. PEG-2 diisononanoate was also found to be safe as used. Because there were little data available on the individual ingredients in these safety assessments, the Panel relied on read across and information on the moieties of these ingredients.

Of the ingredients in this safety assessment, PEG-150 distearate was reported to have the highest number of uses at 690 (an increase from 187 in 1996). Most of these uses are in bath and personal cleansing products and shampoos. The rest of the ingredients are reported to have 48 or fewer uses. PEG-150 distearate was reported to have the highest concentration of use at up to 33.2% (an increase from 5% in 1995). PEG-150 distearate is reported to be used in a rinse-off baby product at up to 9.4%, bath products at up to 4.5%, and in skin cleansing products up to 33.2%. PEG-4 dilaurate and PEG-8 dilaurate were reported to be used at up to 25% in 1984, and are currently used at up to 12% and 15%, respectively. The rest of the ingredients were reported to be used at 15% or less.

Neither PEG-8 dioleate nor PEG-8 dilaurate at 5% enhanced the dermal penetration of ketoprofen through mouse skin when added to a drug delivery plaster preparation. PEG-12 dioleate at 5% did enhance the dermal penetration of ketoprofen with an ER of  $1.54\pm0.22$ .

The oral LD<sub>50</sub> values reported for PEG-4 diheptanoate in rats ranged from >2->25 g/kg.

Vaporized PEG-4 diheptanoate was lethal within 4 h to rats at 14.2 mg/L but not at 13.7 mg/L. Clinical signs included salivation, red nasal discharge, and irregular respiration during the exposure period. The rats recovered quickly during the recovery period.

There were no adverse effects observed when 1 g/kg PEG-4 diheptanoate was administered by gavage to rats for 28 consecutive days.

In the repeated inhalation exposure of vaporized PEG-4 diheptanoate at 1.0 mg/L for 6 h/day, 5 days/week for 4 weeks, clinical signs for rats were mild salivation, reduced response to auditory stimulation, and shallow, rapid respiration sporadically during the exposure periods.

PEG-4 diheptanoate was not mutagenic in a reverse mutation assay up to 10 000 µg/plate using S. typhimurium or in a mammalian cell gene mutation assay using Chinese hamster ovary cells up to 23.9 mM.

At 100%, PEG-4 diheptanoate caused slight to moderate erythema and edema when administered to rabbit skin for 24 h. There was no skin irritation observed in guinea pigs treated with PEG-4 diheptanoate at 5% or 25% but mild irritation was observed in 1 of 3 guinea pigs at 50% and in 3 of 3 at 100%.

There were no lasting reactions observed when PEG-4 diheptanoate at 100% was instilled in the conjunctival sac of rabbits.

In a dermal sensitization study using guinea pigs, PEG-4 diheptanoate at 5% or 25% was not sensitizing when challenged at 5% or 50%.

#### DISCUSSION

Because these ingredients are similarly structured fatty acid diesters with a PEG core and have similar functions in cosmetics, the Panel agreed with combining the PEG distearates, PEG dilaurates, and other similar PEG-diester ingredients into a single report.

Although there are data gaps for individual PEG diesters, the similar chemical structures, physicochemical properties, and functions and concentrations used in cosmetics allow grouping these ingredients together and interpolating the available toxicological data to support the safety of the entire group. Data from previous reports, on chemically analogous ingredients, and on the components of these ingredients were also used to evaluate the safety of these ingredients. It should be noted that although the conclusion in the 2000 report of PEG dilaurates limited their use in cosmetics to concentrations up to 25%, the data presented in this report alleviated the need for that limitation.

Because some of the components of the PEG diesters are obtained from plant sources (eg, PEG-8 ditallate, PEG-12 ditallate, and PEG-8 dicocoate), the Panel expressed concern about pesticide residues and heavy metals that may be present in botanical ingredients. The Panel was also concerned about the possible presence of 1,4-dioxane and ethylene oxide impurities. They stressed that the cosmetics industry should continue to use current good manufacturing practices (cGMPs) to limit impurities in the ingredient before blending into cosmetic formulations.

The Panel recognized that these ingredients, particularly PEG-12 dioleate, can enhance the penetration of other compounds through the skin (eg, ketoprofen). The Panel cautioned that care should be taken in formulating cosmetic products that may contain these ingredients in combination with any ingredients whose safety was based on their lack of dermal absorption data, or when dermal absorption was a concern.

#### AMENDED CONCLUSION

The CIR Expert Panel concluded that the following ingredients are safe in cosmetics when formulated to be nonirritating. This conclusion supersedes the earlier conclusions issued by the Expert Panel in 1999, 2000, and 2011.

PEG-150 dibehenate*	PEG-16 dilaurate*	PEG-4 distearate
PEG-3 dicaprylate/caprate*	PEG-20 dilaurate*	PEG-6 distearate
PEG-4 dicocoate*	PEG-32 dilaurate*	PEG-8 distearate
PEG-8 dicocoate	PEG-75 dilaurate*	PEG-9 distearate
PEG-4 diheptanoate	PEG-150 dilaurate*	PEG-12 disteara
PEG-2 diisononanoate	PEG-2 dioleate*	PEG-20 disteara
PEG-2 diisostearate*	PEG-3 dioleate*	PEG-32 disteara
PEG-3 diisostearate*	PEG-4 dioleate*	PEG-40 disteara
PEG-4 diisostearate*	PEG-6 dioleate*	PEG-50 disteara
PEG-6 diisostearate	PEG-8 dioleate	PEG-75 disteara
PEG-8 diisostearate	PEG-10 dioleate*	PEG-120 distear
PEG-12 diisostearate	PEG-12 dioleate	PEG-150 distear
PEG-90 diisostearate	PEG-20 dioleate*	PEG-175 distear
PEG-175 diisostearate	PEG-32 dioleate*	PEG-190 distear
PEG-2 dilaurate*	PEG-75 dioleate*	PEG-250 distear
PEG-4 dilaurate	PEG-150 dioleate*	PEG-8 ditallate*
PEG-6 dilaurate*	PEG-3 dipalmitate*	PEG-12 ditallate
PEG-8 dilaurate	PEG-2 distearate	
PEG-12 dilaurate*	PEG-3 distearate	

te te te te\* ate ate\* ate\* ate\* ate ate\* arate arate arate arate\* arate te\*

\*Not reported to be in current use. Were ingredients in this group not in current use to be used in the future, the expectation is that they would be used in product categories and at concentrations comparable to others in this group.

# **TABLES**

Ingredient and CAS No.	Definition/structure	Function
PEG-2 distearate 109-30-8	PEG-2 distearate is the polyethylene glycol diester of stearic acid that conforms to the	Surfactant –
109-30-8 52668-97-0	formula:	emulsifying agent
9005-08-7 (generic)		
Joos-oo-7 (generic)	$ \underset{CH_{3}(CH_{2})_{16}C}{\overset{O}{\amalg}} \underset{(OCH_{2}CH_{2})_{n}O}{\overset{O}{\amalg}} \underset{C(CH_{2})_{16}CH_{3}}{\overset{O}{\amalg}} $	
	$CH_3(CH_2)_{16}C - (OCH_2CH_2)_n O - C(CH_2)_{16}CH_3$	
PEG-3 distearate	where n has an average value of 2. PEG-3 distearate is the polyethylene glycol diester of stearic acid that conforms to the	S
9005-08-7 (generic)	formula:	Surfactant – emulsifying agent
9003-08-7 (generic)	â â	enfulsitying agent
	$ \underset{CH_3(CH_2)_{16}C}{\overset{\cup}{\amalg}} \underset{(OCH_2CH_2)_{\pi}O}{\overset{\cup}{\amalg}} \underset{CH_2(CH_2)_{16}CH_3}{\overset{\cup}{\amalg}} $	
PEG-4 distearate	where n has an average value of 3. PEG-4 distearate is the polyethylene glycol diester of stearic acid that conforms to the	Surfactant –
142-20-1	formula:	emulsifying agent
9005-08-7 (generic)		ennansnijing ugenn
(g)	$ \begin{matrix} \bigcirc \\ \parallel \\ CH_3(CH_2)_{16}C - (OCH_2CH_2)_nO - C(CH_2)_{16}CH_3 \end{matrix} $	
	$CH_3(CH_2)_{16}C - (OCH_2CH_2)_nO - C(CH_2)_{16}CH_3$	
PEG-6 distearate	where n has an average value of 4. PEG-6 distearate is the polyethylene glycol diester of stearic acid that conforms to the	Surfactant -
9005-08-7 (generic)	formula:	emulsifying agent
	0 0	
	$\underset{CH_{3}(CH_{2})_{16}C}{\overset{\cup}{\amalg}} \underset{(OCH_{2}CH_{2})_{n}O}{\overset{\cup}{\amalg}} \underset{(CH_{2})_{16}CH_{3}}{\overset{\cup}{\amalg}} \underset{(CH_{2})_{16}CH_{3}}{\overset{\cup}{\sqcup}} \underset{(CH_{2})_{16}CH_{3}}{\overset{\sqcup}{\sqcup}} \underset{(CH_{2})_{16}CH_{3}}{\overset{\sqcup}{\sqcup}} \underset{(CH_{2})_{16}CH_{3}}{\overset{\sqcup}{\sqcup}} \underset{(CH_{2})_{16}CH_{3}}{\overset{\sqcup}{\sqcup}} \underset{(CH_{2})_{16}CH_{3}}{\overset{\sqcup}{\sqcup}} \underset{(CH_{2})_{16}CH_{3}}{\overset{\sqcup}{\sqcup}} \underset{(CH_{2})_{16}CH_{3}}{\overset{U}{\sqcup}} \underset{(CH_{2})_{16}CH_{3}}{U$	
	where n has an average value of 6. PEG-8 distearate is the polyethylene glycol diester of stearic acid that conforms to the	
PEG-8 distearate		Surfactant –
9005-08-7 (generic)	formula:	emulsifying agent
	$\begin{array}{c} & & \\ & & \\ & \\ & \\ & \\ & \\ & \\ & \\ & $	
	where n has an average value of 8. PEG-9 distearate is the polyethylene glycol diester of stearic acid that conforms to the	0.0.4
PEG-9 distearate 109-34-2	formula:	Surfactant – emulsifying agent
9005-08-7 (generic)		enfulsitying agent
Joos of (generic)	$\begin{array}{c} \bigcirc \\ \square \\$	
PEG-12 distearate	where n has an average value of 9. PEG-12 distearate is the polyethylene glycol diester of stearic acid that conforms to	Surfactant -
9005-08-7 (generic)	the formula:	emulsifying agent
Joos-oo-7 (generic)	0	enfulsitying agent
	$\underset{CH_3(CH_2)_{16}C}{\overset{\cup}{\amalg}} \underset{(OCH_2CH_2)_{\pi}O}{\overset{\cup}{\amalg}} \underset{CH_2(CH_2)_{16}CH_3}{\overset{\cup}{\amalg}}$	
PEG-20 distearate	where n has an average value of 12. PEG-20 distearate is the polyethylene glycol diester of stearic acid that conforms to	Surfactant -
9005-08-7 (generic)	the formula:	emulsifying agent
		2 6 6
	$\begin{array}{c} O \\ H \\ CH_3(CH_2)_{16}C - (OCH_2CH_2)_n O - C(CH_2)_{16}CH_3 \end{array}$	
	$CH_3(CH_2)_{16}\ddot{C}$ — $(OCH_2CH_2)_nO$ — $\ddot{C}(CH_2)_{16}CH_3$	
	where n has an average value of 20.	
PEG-32 distearate	PEG-32 distearate is the polyethylene glycol diester of stearic acid that conforms to	Surfactant –
9005-08-7 (generic)	the formula:	emulsifying agent
	0 0	
	$\underset{CH_3(CH_2)_{16}C}{\overset{\bigcup}{\amalg}} - (OCH_2CH_2)_nO - C(CH_2)_{16}CH_3$	
<b>DEG</b> 40 1	where n has an average value of 32.	<u> </u>
PEG-40 distearate	PEG-40 distearate is the polyethylene glycol diester of stearic acid that conforms to	Surfactant –
9005-08-7 (generic)	the formula:	emulsifying agent
	$\begin{array}{c} H \\ H_{3}(CH_{2})_{16}C - (OCH_{2}CH_{2})_{n}O - C(CH_{2})_{16}CH_{3} \end{array}$	
	where n has an average value of 40.	

**Table 1.** The definitions and functions of the PEG diesters in this safety assessment.<sup>1</sup>

Ingredient and CAS No.	Definition/structure	Function
PEG-75 distearate 9005-08-7 (generic)	PEG-75 distearate is the polyethylene glycol diester of stearic acid that conforms to the formula: $\begin{array}{c} O \\    \\ CH_3(CH_2)_{16}C - (OCH_2CH_2)_n O - C(CH_2)_{16}CH_3 \end{array}$	Surfactant – emulsifying agent; surfactant – solubilizing agent
PEG-120 distearate 9005-08-7 (generic)	where n has an average value of 75. PEG-120 distearate is the polyethylene glycol diester of stearic acid that conforms to the formula: $\begin{array}{c} O \\    \\ CH_3(CH_2)_{16}C - (OCH_2CH_2)_n O - C(CH_2)_{16}CH_3 \end{array}$	Surfactant – emulsifying agent; surfactant – solubilizing agent
	where n has an average value of 120.	
PEG-150 distearate 9005-08-7 (generic)	where n has an average value of 120. PEG-150 distearate is the polyethylene glycol diester of stearic acid that conforms to the formula: $\begin{array}{c} \bigcirc & \bigcirc \\ \parallel & & \\ \mathbb{CH}_{3}(\mathbb{CH}_{2})_{16}\mathbb{C} - (\mathbb{OCH}_{2}\mathbb{CH}_{2})_{n0} - \mathbb{C}(\mathbb{CH}_{2})_{16}\mathbb{CH}_{3} \end{array}$	Surfactant – cleansing agent; surfactant – solubilizing agent
DEC 175 1.	where n has an average value of 150.	0 0 4 1 1
PEG-175 distearate 9005-08-7 (generic)	PEG-175 distearate is the polyethylene glycol diester of stearic acid that conforms to the formula: $\begin{array}{c} \bigcirc & \bigcirc \\ & \parallel \\ & \bigcirc \\ & \square $	Surfactant – cleansing agent; surfactant – solubilizing agent
PEG-190 distearate 9005-08-7 (generic)	where n has an average value of 175. PEG-190 distearate is the polyethylene glycol diester of stearic acid that conforms generally to the formula: $\begin{array}{c} & & \\ $	Surfactant – cleansing agent; surfactant – emulsifying agent; surfactant –
	$C_{17}H_{35}\ddot{C}$ (OCH <sub>2</sub> CH <sub>2</sub> ) <sub>n</sub> O $-\dot{C}C_{17}H_{35}$ where n has an average value of 190.	solubilizing agent; viscosity increasing agent – aqueous
PEG-250 distearate 9005-08-7 (generic)	PEG-250 distearate is the polyethylene glycol diester of stearic acid that conforms generally to the formula:	Surfactant – cleansing agent; surfactant – solubilizing agent
	$\begin{array}{c} \bigcirc & \bigcirc \\    &    \\ CH_3(CH_2)_{16}C - (OCH_2CH_2)_n O - C(CH_2)_{16}CH_3 \end{array}$ where n has an average value of 250.	
PEG-150 dibehenate No CAS No.	PEG-150 dibehenate is the polyethylene glycol diester of behenic acid that conforms generally to the formula:	Surfactant – cleansing agent; surfactant – solubilizing agent
	$\begin{array}{c} & & \\ & & \\ & & \\ & \\ & \\ & \\ & \\ & \\ $	
PEG-3 dicaprylate/caprate 68583-52-8	PEG-3 dicaprylate/caprate is the polyethylene glycol diester of a mixture of caprylic and capric acids containing an average of 3 moles of ethylene oxide $0 \qquad 0 \qquad$	Surfactant – emulsifying agent
	where n has an average value of 3 and RCO- represents the residue of either caprylic	
PEG-4 dicocoate	or capric acid [R is a 7 or 9 carbon alkyl chain]. PEG-4 dicocoate is the polyethylene glycol diester of coconut acid that conforms	Skin-conditioning
69278-77-9	generally to the formula: $ \begin{array}{c}                                     $	agent – emollient; surfactant – emulsifying agent
	$RC = (UCH_2CH_2h_0) = CR$ where n has an average value of 4 and RCO- represents the fatty acids derived from coconut oil.	
PEG-8 dicocoate No CAS No.	PEG-8 dicocoate is the polyethylene glycol diester of coconut acid that conforms generally to the formula:	Surfactant – emulsifying agent
	where n has an average value of 8 and RCO- represents the fatty acids derived from	
PEG-4 diheptanoate	coconut oil. PEG-4 diheptanoate is the polyethylene glycol diester of heptanoic acid that conforms	Skin-conditioning
70729-68-9	The formula: $\begin{array}{c} \bigcirc & \bigcirc \\ \square & \square & \square & \bigcirc \\ \square & \square & \square & \bigcirc \\ \square & \square & \square & \square & \bigcirc \\ \square & \square & \square & \square & \square & \square \\ \square & \square & \square & \square$	agent – emollient; surfactant – emulsifying agent

Table 1.	. The definitions and functions of the PEG diesters in this safety assessment. <sup>1</sup>	1
----------	---	---

Ingredient and CAS No. **Definition/structure** Function PEG-2 diisononanoate PEG-2 diisononanoate is the polyethylene glycol diester of isononanoic acid that Surfactant -No CAS No. conforms to the formula: emulsifying agent C8H17C (OCH<sub>2</sub>CH<sub>2</sub>), where n has an average value of 2. PEG-2 diisostearate PEG-2 diisostearate is the polyethylene glycol diester of isostearic acid that conforms Surfactant -No CAS No. generally to the formula: emulsifying agent C17H35C (OCH<sub>2</sub>CH<sub>2</sub>)<sub>n</sub>O CC17H35 where n has an average value of 2. PEG-3 diisostearate PEG-3 diisostearate is the polyethylene glycol diester of isostearic acid that conforms Surfactant -No CAS No. generally to the formula: emulsifying agent (OCH<sub>2</sub>CH<sub>2</sub>)<sub>n</sub>O -- CC<sub>17</sub>H<sub>35</sub> C17H35Cwhere n has an average value of 3. PEG-4 diisostearate PEG-4 diisostearate is the polyethylene glycol diester of isostearic acid that conforms Surfactant -No CAS No. generally to the formula: emulsifying agent where n has an average value of 4 PEG-6 diisostearate PEG-6 diisostearate is the polyethylene glycol diester of isostearic acid that conforms Surfactant -No CAS No. generally to the formula: emulsifying agent C17H35 (OCH2CH2),O where n has an average value of 6. PEG-8 diisostearate PEG-8 diisostearate is the polyethylene glycol diester of isostearic acid that conforms Surfactant -No CAS No. to the formula: emulsifying agent (OCH2CH2)nO C17H35C CC17H35 where n has an average value of 8. PEG-12 diisostearate PEG-12 diisostearate is the polyethylene glycol diester of isostearic acid that Surfactant -No CAS No. conforms generally to the formula: emulsifying agent ĬĬ C17H35C (OCH2CH2)nO CC17H35 where n has an average value of 12. PEG-90 diisostearate PEG-90 diisostearate is the polyethylene glycol diester of isostearic acid that Surfactant – cleansing No CAS No. conforms generally to the formula: agent C17H35C (OCH2CH2)nO CC17H35 where n has an average value of 90. PEG-175 diisostearate PEG-175 diisostearate is the polyethylene glycol diester of isostearic acid that Surfactant -No CAS No. conforms generally to the formula: emulsifying agent; viscosity increasing agent - aqueous (OCH<sub>2</sub>CH<sub>2</sub>)<sub>n</sub>O-C17H35C ·CC17H35 where n has an average value of 175. PEG-2 dilaurate PEG-2 dilaurate is the polyethylene glycol diester of lauric acid that conforms to the Surfactant -6281-04-5 emulsifying agent formula: 9005-02-1 (generic) CH3(CH2)10C C(CH2)10CH3 (OCH<sub>2</sub>CH<sub>2</sub>)<sub>n</sub>O where n has an average value of 2. PEG-4 dilaurate PEG-4 dilaurate is the polyethylene glycol diester of lauric acid that conforms to the Surfactant -9005-02-1 (generic) formula: emulsifying agent CH3(CH2)10C (OCH2CH2)nO C(CH<sub>2</sub>)<sub>10</sub>CH<sub>3</sub> where n has an average value of 4. PEG-6 dilaurate PEG-6 dilaurate is the polyethylene glycol diester of lauric acid that conforms to the Surfactant -9005-02-1 (generic) emulsifying agent formula: CH3(CH2)10C (OCH2CH2)nO C(CH2)10CH3 where n has an average value of 6.

Ingredient and CAS No.	Definition/structure	Function
PEG-8 dilaurate 9005-02-1 (generic)	PEG-8 Dilaurate is the polyethylene glycol diester of lauric acid that conforms to the formula:	Surfactant – emulsifying agent
(generic)	0 0	ennansnijing ugente
	$\overset{II}{\underset{CH_3(CH_2)_{10}C}{\sqcup}} - (OCH_2CH_2)_{nO} - \overset{II}{C(CH_2)_{10}CH_3}}$	
	where n has an average value of 8.	9 6 4 4
PEG-12 dilaurate 0005-02-1 (generic)	PEG-12 Dilaurate is the polyethylene glycol diester of lauric acid that conforms to the formula:	Surfactant – emulsifying agent
	$\begin{array}{c} O \\ II \\ CH_3(CH_2)_{10}C - (OCH_2CH_2)_{n}O - C(CH_2)_{10}CH_3 \end{array}$	
	where n has an average value of 12	
PEG-16 dilaurate 2005-02-1 (generic)	PEG-16 Dilaurate is the polyethylene glycol diester of lauric acid that conforms generally to the formula:	Surfactant – emulsifying agent
	О    СН <sub>3</sub> (СН <sub>2</sub> ) <sub>10</sub> С — (ОСН <sub>2</sub> СН <sub>2</sub> ) <sub>1</sub> О — С(СН <sub>2</sub> ) <sub>10</sub> СН <sub>3</sub>	
	where n has an average value of 16.	
PEG-20 dilaurate 9005-02-1 (generic)	PEG-20 dilaurate is the polyethylene glycol diester of lauric acid that conforms to the formula:	Surfactant – emulsifying agent
	$ \underset{CH_{3}(CH_{2})_{10}C}{\overset{O}{\amalg}} \underset{(OCH_{2}CH_{2})_{n}O}{\overset{O}{\amalg}} \underset{(CH_{2})_{10}CH_{3}}{\overset{O}{\amalg}} $	
	where n has an average value of 20.	
PEG-32 dilaurate 9005-02-1 (generic)	PEG-32 dilaurate is the polyethylene glycol diester of lauric acid that conforms to the formula:	Surfactant – emulsifying agent
	СH <sub>3</sub> (CH <sub>2</sub> ) <sub>10</sub> С — (ОСH <sub>2</sub> CH <sub>2</sub> ) <sub>1</sub> О — С(CH <sub>2</sub> ) <sub>10</sub> CH <sub>3</sub>	
	where n has an average value of 32.	
PEG-75 dilaurate 9005-02-1 (generic)	PEG-75 dilaurate is the polyethylene glycol diester of lauric acid that conforms to the formula:	Surfactant – cleansing agent; surfactant –
	$ \underset{CH_{3}(CH_{2})_{10}C}{\overset{O}{\amalg}} \underset{(OCH_{2}CH_{2})_{n}O}{\overset{O}{\amalg}} \underset{(CH_{2}CH_{2})_{10}C}{\overset{O}{\amalg}} \underset{(CH_{2}CH_{2})_{10}C}{\overset{O}{\sqcup}} \underset{(CH_{2}CH_{2})_{10}C}{\overset{O}{\sqcup$	solubilizing agent
	where n has an average value of 75	
PEG-150 dilaurate 9005-02-1 (generic)	PEG-150 dilaurate is the polyethylene glycol diester of lauric acid that conforms to the formula:	Surfactant – cleansing agent; surfactant –
	$ \begin{matrix} \cup \\    \\ CH_3(CH_2)_{10}C - (OCH_2CH_2)_nO - C(CH_2)_{10}CH_3 \end{matrix} $	solubilizing agent
	where n has an average value of 150.	
PEG-2 dioleate No CAS No.	PEG-2 dioleate is the polyethylene glycol diester of oleic acid that conforms generally to the formula:	Surfactant – emulsifying agent
	$\begin{array}{c}    \\ CH(CH_2)_7C \longrightarrow (OCH_2CH_2)_nO \longrightarrow C(CH_2)_7CH \\    \\ CH(CH_2)_7CH_3 & CH_3(CH_2)_7CH \end{array}$	
	where n has an average value of 2.	
PEG-3 dioleate	PEG-3 dioleate is the polyethylene glycol diester of oleic acid that conforms generally	Surfactant –
No CAS No.	to the formula:	emulsifying agent
	$\begin{array}{c} & & & \\ & & & \\ CH(CH_2)_7C \longrightarrow (OCH_2CH_2)_nO \longrightarrow C(CH_2)_7CH \\ H \\ CH(CH_2)_7CH_3 & CH_3(CH_2)_7CH \end{array}$	
	$UH_{1}(UH_{2})_{7}UH_{3}$ $UH_{3}(UH_{2})_{7}UH$	
PEG-4 dioleate 134141-38-1	where n has an average value of 3. PEG-4 dioleate is the polyethylene glycol diester of oleic acid that conforms to the formula:	Surfactant – emulsifying agent
52668-97-0 (generic) 9005-07-6 (generic)		
	Ш Ц Сн(Сн <sub>2</sub> ) <sub>7</sub> С — (ОСн <sub>2</sub> Сн <sub>2</sub> ) <sub>n</sub> О — С(Сн <sub>2</sub> ) <sub>7</sub> Сн Ц Сн(Сн <sub>2</sub> ) <sub>7</sub> Сн <sub>3</sub> Сн <sub>3</sub> (Сн <sub>2</sub> ) <sub>7</sub> Сн	
	where n has an average value of 4.	~ ~
PEG-6 dioleate 52668-97-0 (generic) 9005-07-6 (generic)	PEG-6 dioleate is the polyethylene glycol diester of oleic acid that conforms to the formula:	Surfactant – emulsifying agent
, cos or o (generic)	О II СH(CH <sub>2</sub> ) <sub>7</sub> С — (ОСН <sub>2</sub> СН <sub>2</sub> ) <sub>n</sub> О — С(СН <sub>2</sub> ) <sub>7</sub> СН II СH(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub> СН <sub>3</sub> (СН <sub>2</sub> ) <sub>7</sub> CH	
	II II CH(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub> CH <sub>3</sub> (CH <sub>2</sub> ) <sub>2</sub> CH	
	where n has an average value of 6.	

Table 1. The definitions and functions of the PEG diesters in this safety assessment.<sup>1</sup>

Ingredient and CAS No.	Definition/structure	Function
PEG-8 dioleate 52668-97-0 (generic)	PEG-8 dioleate is the polyethylene glycol diester of oleic acid that conforms to the formula:	Surfactant – emulsifying agent
9005-07-6 (generic)		
	$\begin{array}{c} & & & \\ & & & \\ CH(CH_2)_7C & (OCH_2CH_2)_nO & C(CH_2)_7CH \\ H & & H \\ CH(CH_2)_7CH_3 & CH_3(CH_2)_7CH \end{array}$	
PEG-10 dioleate	where n has an average value of 8. PEG-10 dioleate is the polyethylene glycol diester of oleic acid that conforms to the	Surfactant –
52668-97-0 (generic)	formula:	emulsifying agent
9005-07-6 (generic)		
	Сн(Сн <sub>2</sub> ) <sub>7</sub> С — (ОСн₂Сн₂) <sub>0</sub> О — С(Сн₂) <sub>7</sub> Сн    Сн(Сн₂) <sub>7</sub> Сн₃ Сн₃(Сн₂) <sub>7</sub> Сн	
	where n has an average value of 10.	
PEG-12 dioleate	PEG-12 dioleate is the polyethylene glycol diester of oleic acid that conforms to the	Surfactant –
52668-97-0 (generic)	formula:	emulsifying agent
9005-07-6 (generic)	$\begin{array}{c} & \bigcirc & & \bigcirc \\ & \parallel & & \parallel \\ & \square & & \square \\ & \square & (CH(CH_2)_7C (OCH_2CH_2)_nO C(CH_2)_7CH \\ & \parallel & & \parallel \\ & \square & & \square \\ & CH(CH_2)_7CH_3 & CH_3(CH_2)_7CH \end{array}$	
	CH(CH <sub>2</sub> ) <sub>7</sub> C (OCH <sub>2</sub> CH <sub>2</sub> ) <sub>n</sub> O C(CH <sub>2</sub> ) <sub>7</sub> CH	
	$CH(CH_2)_7CH_3$ $CH_3(CH_2)_7CH$	
PEG-20 dioleate	where n has an average value of 12. PEG-20 dioleate is the polyethylene glycol diester of oleic acid that conforms to the	Surfactant –
52668-97-0 (generic)	formula:	emulsifying agent
9005-07-6 (generic)	O O	
	CH(CH <sub>2</sub> ) <sub>7</sub> C (OCH <sub>2</sub> CH <sub>2</sub> ) <sub>7</sub> OC(CH <sub>2</sub> ) <sub>7</sub> CH	
	$\begin{array}{c} & & & & \\ & & & \\ CH(CH_2)_7C & (OCH_2CH_2)_nO & C(CH_2)_7CH \\ II & & & \\ II \\ CH(CH_2)_7CH_3 & & CH_3(CH_2)_7CH \end{array}$	
	where n has an average value of 20. $CH_{3}(CH_{2})_{7}CH_{3}$	
PEG-32 dioleate	PEG-32 dioleate is the polyethylene glycol diester of oleic acid that conforms to the	Surfactant –
52668-97-0 (generic)	formula:	emulsifying agent
9005-07-6 (generic)		
	$ \begin{array}{c} & & & & \\ & & & \\ CH(CH_2)_7C & & & \\ H \\ H \\ CH(CH_2)_7CH_3 & & CH_3(CH_2)_7CH \end{array} $	
	II CH(CHa)-CHa CHa(CHa)-CH	
	where n has an average value of 32.	
PEG-75 dioleate	PEG-75 dioleate is the polyethylene glycol diester of oleic acid that conforms to the	Surfactant - cleansing
52668-97-0 (generic) 9005-07-6 (generic)	formula:	agent; surfactant – solubilizing agent
9003-07-0 (generic)	$\begin{array}{c} & & & & \\ & & & \\ CH(CH_2)_7C (OCH_2CH_2)_7OC(CH_2)_7CH \\ & & & \\ H \\ CH(CH_2)_7CH_3 \\ \end{array}$	solubilizing agent
	CH(CH <sub>2</sub> ) <sub>7</sub> C — (OCH <sub>2</sub> CH <sub>2</sub> ) <sub>n</sub> O — C(CH <sub>2</sub> ) <sub>7</sub> CH	
	Сн(сн <sub>2</sub> ) <sub>7</sub> сн <sub>3</sub> сн <sub>3</sub> (сн <sub>2</sub> ) <sub>7</sub> сн	
PEG-150 dioleate	where n has an average value of 75. PEG-150 dioleate is the polyethylene glycol diester of oleic acid that conforms to the	Surfactant classing
52668-97-0 (generic)	formula:	Surfactant – cleansing agent
9005-07-6 (generic)		
	$\begin{matrix} \bigcirc & & & \\    & &    \\ CH(CH_2)_7C (OCH_2CH_2)_nO C(CH_2)_7CH \\    & & &    \\ CH(CH_2)_7CH_3 & CH_3(CH_2)_7CH \end{matrix}$	
	where n has an average value of 150.	
PEG-3 dipalmitate	PEG-3 dipalmitate is the polyethylene glycol diester of palmitic acid that conforms	Surfactant -
32628-06-1 (generic)	generally to the formula:	emulsifying agent
	$ \begin{matrix} \bigcirc \\    \\ CH_3(CH_2)_{14}C - (OCH_2CH_2)_{10}O - C(CH_2)_{14}CH_3 \end{matrix} $	
	where n has an average value of 3.	
PEG-8 ditallate	PEG-8 ditallate is the polyethylene glycol diester of tall oil acid that conforms	Surfactant –
61791-01-3 (generic)	generally to the formula:	emulsifying agent
	$ \begin{matrix} 0 \\    \\ RC - (OCH_2CH_2)_0 O - CR \end{matrix} $	
PEG-12 ditallate	where RCO- represents the tall oil fatty radicals and n has an average value of 8. PEG-12 ditallate is the polyethylene glycol diester of tall oil acid that conforms	Surfactor
61791-01-3 (generic)	generally to the formula:	Surfactant – emulsifying agent
Server a (Berrette)		Jung agoin
	$ \begin{array}{c} O & O \\ II \\ RC - (OCH_2CH_2)_n O - CR \end{array} $	
	RC — $(OCH_2CH_2)_nO$ — CR where RCO- represents the tall oil fatty radicals and n has an average value of 12.	
	where ited - represents the ran on rarry radicals and it has an average value of 12.	

Table 1. The definitions and functions of the PEG diesters in this safety assessment.<sup>1</sup>

# **Table 2.** Previous safety assessment of PEG diesters and component moieties of the ingredients in this safety assessment.

		Maximum concentration in safety	D
Ingredients	Conclusion	assessment	Reference
Previous safety assessment of PEG diesters			
PEG diesters - PEG-2 distearate, PEG-3 distearate, PEG-4 distearate, PEG-6	Safe for use in cosmetic	5%	2
distearate, PEG-8 distearate, PEG-9 distearate, PEG-12 distearate PEG-20	formulations under the		
distearate, PEG-32 distearate, PEG-50 distearate, PEG-75 distearate, PEG-120	present practices of use.		
distearate, PEG-150 distearate, PEG-175 distearate			
PEG Dilaurates – PEG-2 dilaurate, PEG-4 dilaurate, PEG-6 dilaurate, PEG-8	Safe for use in cosmetics at	25%	3
dilaurate, PEG-12 dilaurate, PEG-16 dilaurate, PEG-20 dilaurate, PEG-32	concentrations up to 25%.		
dilaurate, PEG-75 dilaurate, PEG-150 dilaurate			
(also included PEG-2, -4, -6, -8, -9, -10, -12, -14, -20, -32, -75, -150, and -200			
Laurate; and PEG-2 Laurate SE)	0.0	740/	4
<b>PEG-2 diisononanoate</b> (included with nonanoic and and its nonanoate esters)	Safe as cosmetic	74%	
	ingredients in the present practices of use and		
	concentration		
	described in this safety		
	assessment		
Safety assessments on related moieties			
Coconut oil, acid and related ingredients	Safe as used	100%	6-8,15
Isostearic acid	Safe as used.	26%	8,10
Oleic acid, lauric acid, stearic acid	Safe as used.	> 50%; 43%	9,11
PEGS	Safe as used.	85%	12-14
PEG stearates	Safe as used.	25%	8,17
Stearates	Safe as used	87%	8,16
Steareths	Safe when formulated to	25%; 32% in	19-21
	be nonirritating	products	
		diluted for the	
		bath	18
Tall oil acid, sodium tallate, potassium tallate, ammonium tallate	Safe as used.	8%	10

## Table 3. Chemical and physical properties of PEG diesters.

Property	Value	Reference
PGE	-4 diheptanoate	
Physical Form	Liquid	25
Color	Clear	25
Density/Specific Gravity	0.996	25
Vapor pressure mmHg@ 37°C	<0.1	25
Boiling Point °C	>300	25
Other Solubility g/L		
Alcohol	Soluble	25
Acetone	Soluble	25
PE	G-4 dilaurate	
Physical Form	Viscous (oily) liquid	24
Color	Pale yellow	24
Density/Specific Gravity @ 25°C	0.96	43
Melting Point °C	<14	44
Water Solubility	Dispersible	24
Other Solubility	<b>k</b>	
Mineral oil	Soluble	24
Acetone	Soluble	24
Isopropyl alcohol	Soluble	24
РЕ	G-8 dilaurate	
Physical Form	Liquid	24
Color	Clear, pale yellow	24
Odor	Slightly fatty	24
Density/Specific Gravity @ 25°C	0.985-0.995	24
Water Solubility	Dispersible	
Other Solubility	*	
Isopropyl alcohol	Soluble	45
Acetone	Soluble	46
Mineral oil	Soluble	47

	Table 3.	Chemical	and	physical	properties	of PEG	diesters.
--	----------	----------	-----	----------	------------	--------	-----------

Property	Value	Reference
I	PEG-150 dilaurate	
Physical Form	Waxy solid	24
Color	Tan	24
Odor	Slightly fatty odor	24
Melting Point °C	53-60	24
Water Solubility	Soluble	24
Other Solubility		
Isopropanol	Soluble	24
Toluene	Soluble	24

**Table 4.** Current and historical frequency and concentration of use of PEG diesters according to duration and exposure.4,33,35

	# of l	Uses	Max Conc o	of Use (%)	# of L	lses	Max Conc o	f Use (%)
	2015	1996	2014	1995	2015	1996	2014	1995
		PEG-2	distearate			PEG-3	distearate	
Totals*	6	4	0.001	NR	48	8	0.45-3.4	NR
Duration of Use				•	I.			
Leave-On	6	4	0.001	NR	NR	2	0.45-1.5	NR
Rinse-Off	NR	NR	NR	NR	47	6	0.45-3.4	NR
Diluted for (Bath) Use	NR	NR	NR	NR	1		1.7	NR
Exposure Type		· · · · ·		·	•	· · · ·		
Eye Area	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	2 <sup>a</sup> ; 2 <sup>c</sup>	2 <sup>a</sup> ; 2 <sup>c</sup>	NR	NR	NR	2°	NR	NR
Incidental Inhalation-Powder	$2^{c}$	2°	NR	NR	NR	2°	NR	NR
Dermal Contact	6	4	0.001	NR	36	6	0.45-3	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	NR	NR	12	2	1-3.4	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	2.8	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	NR	NR	NR	NR	14	NR	0.45-1.7	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR
÷		· · ·		·	•	· · · ·		
	2015	1996	2014	1995	2015	1996	2014	1995
								1775
			distearate				distearate	1775
Totals*	1			NR	1			NR
	1	PEG-4	distearate			PEG-6	distearate	
Duration of Use	1 NR	PEG-4	distearate			PEG-6	distearate	
Totals* Duration of Use Leave-On Rinse-Off		PEG-4 5	distearate NR	NR	1	PEG-6	distearate 0.5-1	NR
Duration of Use Leave-On Rinse-Off	NR	PEG-4 5 NR	distearate NR NR	NR NR	1 NR	PEG-6 1 NR	distearate 0.5-1 0.5-1	NR NR
Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use	NR 1	PEG-4 5 <i>NR NR</i>	distearate NR NR NR NR	NR NR NR	1 NR 1	PEG-6 1 NR 1	distearate 0.5-1 0.5-1 0.91-1	NR NR NR
Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type	NR 1	PEG-4 5 <i>NR NR</i>	distearate NR NR NR NR	NR NR NR	1 NR 1	PEG-6 1 NR 1	distearate 0.5-1 0.5-1 0.91-1	NR NR NR
Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type Eye Area	NR 1 NR	PEG-4 5 NR NR NR	NR NR NR NR NR	NR NR NR NR	1 NR I NR	PEG-6 1 NR 1 NR	distearate 0.5-1 0.91-1 NR	NR NR NR NR
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion	NR 1 NR NR	PEG-4 5 NR NR NR NR	o distearate NR NR NR NR NR	NR NR NR NR	1 NR 1 NR NR	PEG-6 1 NR 1 NR NR NR	distearate 0.5-1 0.91-1 NR NR	NR NR NR NR
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray	NR 1 NR NR NR	PEG-4 5 NR NR NR NR NR	o distearate NR NR NR NR NR NR NR NR	NR NR NR NR NR NR	1 NR I NR NR NR	PEG-6 1 NR 1 NR NR NR NR	distearate 0.5-1 0.91-1 NR NR NR	NR NR NR NR NR
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder	NR 1 NR NR NR NR	PEG-4 5 NR NR NR NR NR NR	o distearate NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR	1 NR I NR NR NR NR	PEG-6 1 NR NR NR NR NR NR	distearate 0.5-1 0.91-1 NR NR NR NR NR	NR NR NR NR NR NR
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder         Dermal Contact	NR 1 NR NR NR NR NR	PEG-4 5 NR NR NR NR NR NR NR NR	distearate NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR	1 NR I NR NR NR NR NR NR	PEG-6 1 NR I NR NR NR NR NR NR NR	distearate 0.5-1 0.91-1 NR NR NR NR NR 1 <sup>b</sup>	NR NR NR NR NR NR NR
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder         Dermal Contact         Deodorant (underarm)	NR 1 NR NR NR NR NR NR NR	PEG-4 5 NR NR NR NR NR NR 1	distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR	1 NR I NR NR NR NR 1	PEG-6 1 NR I NR NR NR NR NR 1 I	distearate 0.5-1 0.91-1 NR NR NR NR NR 1 <sup>b</sup> 0.5-1	NR NR NR NR NR NR NR NR NR
Duration of UseLeave-OnRinse-OffDiluted for (Bath) UseExposure TypeEye AreaIncidental IngestionIncidental Inhalation-SprayIncidental Inhalation-PowderDermal ContactDeodorant (underarm)Hair - Non-Coloring	NR 1 NR NR NR NR NR NR NR NR	PEG-4 5 NR NR NR NR NR NR NR 1 NR	distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR NR	1 NR I NR NR NR NR 1 NR	PEG-6 1 NR I NR NR NR NR NR 1 NR 1 NR 1 NR	distearate 0.5-1 0.91-1 NR NR NR NR 1 <sup>b</sup> 0.5-1 NR	NR NR NR NR NR NR NR NR NR NR
Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type Eye Area	NR 1 NR NR NR NR NR NR NR 1	PEG-4 5 NR NR NR NR NR NR 1 NR 4	distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR NR NR	1 NR I NR NR NR NR I NR NR NR	PEG-6 1 NR I NR NR NR NR NR I NR I NR	distearate 0.5-1 0.91-1 NR NR NR NR 1 <sup>b</sup> 0.5-1 NR 1	NR NR NR NR NR NR NR NR NR NR NR
Duration of UseLeave-OnRinse-OffDiluted for (Bath) UseExposure TypeEye AreaIncidental IngestionIncidental Inhalation-SprayIncidental Inhalation-PowderDermal ContactDeodorant (underarm)Hair - Non-ColoringHair-Coloring	NR 1 NR NR NR NR NR NR NR 1 NR	PEG-4 5 NR NR NR NR NR NR 1 NR 4 NR	distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR NR NR NR N	1 NR I NR NR NR NR I NR NR NR NR NR	PEG-6 1 NR I NR NR NR NR NR I NR	distearate 0.5-1 0.91-1 NR NR NR NR 1 <sup>b</sup> 0.5-1 NR 1 NR 1 NR	NR NR NR NR NR NR NR NR NR NR NR NR

**Table 4.** Current and historical frequency and concentration of use of PEG diesters according to duration and exposure. $_{4,33,35}$ 

	# of i	Uses	Max Conc of	<sup>c</sup> Use (%)	# of L	lses	s Max Conc of	
	2015	1996	2014	1995	2015	1996	2014	1995
		PEG-	8 distearate	2		PEG-12	distearate	
Totals*	48	64	0.0091-7	NR	7	13	0.2-1.7	NR
Duration of Use			•					•
Leave-On	36	23	0.0091-6.5	NR	1	2	NR	NR
Rinse-Off	12	41	7	NR	6	11	0.2-1.7	NR
Diluted for (Bath) Use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure Type			•					
Eye Area	2	NR	0.0091-1.2	NR	NR	NR	NR	NR
Incidental Ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	5ª; 3°	2ª; 3°	0.3ª	NR	NR	NR	NR	NR
Incidental Inhalation-Powder	3°	1; 3 <sup>c</sup>	0.5 <sup>b</sup>	NR	NR	NR	NR	NR
Dermal Contact	42	50	0.0091-7	NR	1	1	NR	NR
Deodorant (underarm)	$10^{a}$	6 <sup>a</sup>	1-6.5 <sup>d</sup>	NR	NR	NR	NR	NR
Hair - Non-Coloring	6	NR	0.3	NR	6	12	0.2-1.7	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	4	26	NR	NR	NR	NR	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR
)		1	: :		•			•
	2015	1996	2014	1995	2015	1996	2014	199
	2015		2014 50 distearate	1995	2015		2014 ) distearate	1995
	2015			1995 NR	2015			
Totals*		PEG-5	50 distearate			PEG-12	) distearate	
Totals* Duration of Use		PEG-5	50 distearate			PEG-12	) distearate	
Totals* Duration of Use Leave-On	1	PEG-5 1	50 distearate NR	NR	7	PEG-120 NR	) distearate NR	NR
Totals* Duration of Use Leave-On Rinse-Off	1 NR	PEG-5 1 NR	50 distearate NR	NR NR	7 NR	PEG-120 NR	) distearate NR NR	
Totals* Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use	1 NR 1	PEG-5 1 NR 1	0 distearate NR NR NR	NR NR NR	7 NR 7	PEG-120 NR NR NR NR	) distearate NR NR NR	NR NR NR
Totals* Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type	1 NR 1	PEG-5 1 NR 1	0 distearate NR NR NR	NR NR NR	7 NR 7 NR	PEG-120 NR NR NR NR	) distearate NR NR NR	NR NR NR
Totals* Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type Eye Area	1 NR 1 NR NR	PEG-5 1 NR 1 NR	0 distearate NR NR NR NR NR	NR NR NR NR	7 <i>NR</i> 7 <i>NR</i> NR	PEG-120 NR NR NR NR NR	) distearate NR NR NR NR NR	NR NR NR NR
Totals* Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type Eye Area Incidental Ingestion	1 NR 1 NR	PEG-5 1 NR 1 NR	0 distearate NR NR NR NR	NR NR NR NR	7 NR 7 NR	PEG-120 NR NR NR NR NR	) distearate NR NR NR NR NR	NR NR NR NR NR
Totals* Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type Eye Area	1 NR I NR NR NR	PEG-5 1 NR 1 NR NR NR NR	0 distearate NR NR NR NR NR NR NR	NR NR NR NR NR NR	7 <i>NR</i> 7 <i>NR</i> NR NR	PEG-120 NR NR NR NR NR NR	) distearate NR NR NR NR NR NR NR	NR NR NR NR NR NR
Totals* Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type Eye Area Incidental Ingestion Incidental Inhalation-Spray Incidental Inhalation-Powder	1 NR I NR NR NR NR	PEG-5 1 NR 1 NR NR NR NR NR	0 distearate NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR	7 NR 7 NR NR NR NR	PEG-120 NR NR NR NR NR NR NR	) distearate NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR
Totals* Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type Eye Area Incidental Ingestion Incidental Inhalation-Spray Incidental Inhalation-Powder Dermal Contact	1 NR I NR NR NR NR NR NR	PEG-5 1 NR I NR NR NR NR NR NR NR	0 distearate NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR	7 NR 7 NR NR NR NR NR NR	PEG-120 NR NR NR NR NR NR NR NR NR	) distearate NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR
Totals* Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type Eye Area Incidental Ingestion Incidental Inhalation-Spray Incidental Inhalation-Powder Dermal Contact Deodorant (underarm)	1 NR I NR NR NR NR NR NR 1	PEG-5 1 NR 1 NR NR NR NR NR 1	0 distearate NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR	7 <i>NR</i> 7 <i>NR</i> NR NR NR NR 7	PEG-120 NR NR NR NR NR NR NR NR NR NR	) distearate NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR
Totals*         Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder         Dermal Contact         Deodorant (underarm)         Hair - Non-Coloring	1 NR I NR NR NR NR NR I NR	PEG-5 1 NR 1 NR NR NR NR 1 NR 1 NR 1 NR 1 NR	0 distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR NR	7 <i>NR</i> 7 <i>NR</i> NR NR NR 7 NR	PEG-120 NR NR NR NR NR NR NR NR NR NR NR NR NR	) distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR NR
Totals* Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type Eye Area Incidental Ingestion Incidental Inhalation-Spray	1 NR I NR NR NR NR I NR NR NR NR	PEG-5 1 NR I NR NR NR NR NR I NR	0 distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR NR NR NR	7 NR 7 NR NR NR NR 7 NR NR NR NR	PEG-120 NR NR NR NR NR NR NR NR NR NR NR NR NR	) distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR
Totals*         Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder         Dermal Contact         Deodorant (underarm)         Hair - Non-Coloring         Hair-Coloring	1 NR I NR NR NR NR I NR NR NR NR NR	PEG-5 1 NR I NR NR NR NR NR I NR	0 distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR NR NR NR N	7 NR 7 NR NR NR NR 7 NR NR NR NR NR	PEG-120 NR NR NR NR NR NR NR NR NR NR NR NR NR	) distearate NR NR NR NR NR NR NR NR NR NR NR NR NR	NR NR NR NR NR NR NR NR NR NR NR NR

**Table 4.** Current and historical frequency and concentration of use of PEG diesters according to duration and exposure.4,33,35

	4,33,3:			35				
	# of U	Jses	Max Conc of	f Use (%)	# of U	# of Uses		Use (%)
	2015	1996	2014	1995	2015	1996	2014	1995
		PEG-150 distearate			PEG-175 distearate			
Totals*	690	187	0.003-33.2	1-5	NR	NR	0.089	NR
Duration of Use		1					I	
Leave-On	54	59	0.006-9	1-5	NR	NR	NR	NR
Rinse-Off	602	101	0.0003-33.2	1-5	NR	NR	0.089	NR
Diluted for (Bath) Use	34	27	1-1.5	1.75	NR	NR	NR	NR
Exposure Type	-		1					
Eye Area	5	2	0.07-1.8	0.5	NR	NR	NR	NR
Incidental Ingestion	NR	NR	0.05	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	16 <sup>a</sup> ; 12 <sup>c</sup>	$10^{\rm a}; 2^{\rm c}$	0.006-2.4ª	NR	NR	NR	NR	NR
Incidental Inhalation-Powder	1; 12°	4; 2°	0.024-9 <sup>b</sup>	NR	NR	NR	NR	NR
Dermal Contact	487	117	0.0003-33.2	1-5	NR	NR	0.089	NR
Deodorant (underarm)	1 <sup>a</sup>	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	202	69	0.006-4.5	1-5	NR	NR	NR	NR
Hair-Coloring	NR	NR	0.0075-0.15	NR	NR	NR	NR	NR
Nail	NR	1	NR	NR	NR	NR	NR	NR
Mucous Membrane	399	42	0.0003-4.5	1.75	NR	NR	NR	NR
Baby Products	26	14	0.75-9.4	NR	NR	NR	NR	NR
Buby Hoducts	20		0.75 7.1	I	1111		THE	1010
	2015	2009	2014	2009	2015	1996	2014	1984
		PEG-2	liisosnosnoate			PEG-4	4 dilaurate	
Totals*	NR	NR	1.7	2	38	15	0.028-12	1-25
Duration of Use				_			01020 12	
Leave-On	NR	NR	1.7	2	18	5	0.032-12	NR
	NR	NR	NR	2 NR	15	1	0.032-12	
Rinse-Off	NR	NR	NR	NR	5	9	NR	NR NR
Diluted for (Bath) Use	IVK	IVK	IVK	IVK	5	9	IVK	NK
Exposure Type								
Eye Area	NR	NR	NR	NR	9	NR	0.04-2	NR
Incidental Ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	NR	NR	NR	NR	6 <sup>a</sup> ; 3 <sup>c</sup>	2ª; 1°	0.072; 0.036 <sup>a</sup>	NR
Incidental Inhalation-Powder	NR	NR	NR	NR	3°	1 <sup>c</sup>	0.036-0.25 <sup>b</sup>	NR
Dermal Contact	NR	NR	NR	NR	32	15	0.028-12	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	NR	NR	6	NR	0.036-0.72	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	1.7	2	NR	NR	NR	NR
Mucous Membrane	NR	NR	NR	NR	7	9	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR
	2015	1996	2014	1984		-	ay be used in cosm	
		PEG	·8 dilaurate				sum of all exposur	e types m
Totals*	10 down	25	0.18-15	0.1-25	not equal the su NR – no report		ses.	
Duration of Use					-		s are sprays, but it i	s not
Leave-On	1	9	6	NR			ed uses are sprays.	
Rinse-Off	3	9	0.18-6	NR			s are powders, but i	t is not
Diluted for (Bath) Use	6	7	15	NR			ed uses are powders, but i	
Exposure Type	-		-			-	ray or a powder, bu	
Exposure Type	-		0.10	ND.	-	-	spray or a powder	

2

NR

 $1^{a}$ 

NR

9

NR

1

NR

NR

6

NR

Eye Area

Incidental Ingestion

Deodorant (underarm)

Hair - Non-Coloring

Mucous Membrane

Dermal Contact

Hair-Coloring

**Baby Products** 

Nail

Incidental Inhalation-Spray

Incidental Inhalation-Powder

NR

NR

NR

NR

11

NR

13

NR

1

7

NR

0.18

NR

6<sup>a</sup>

NR

0.018-15

NR

6

NR

NR

15

NR

	<sup>c</sup> Not specified whether a spray or a powder, but it is
NR	possible the use can be as a spray or a powder, therefore the
111	information is captured in both categories.
NR	<sup>d</sup> Not spray

NR <sup>e</sup> Pump spray

NR

NR

NR

NR

NR

NR

NR

<sup>f</sup> No breakdown of use was provided in the original report.

			duratio	on and exposure	. 33,35			
		Maximum		Maximum		Maximum		Maximum
		Concentration		Concentration		Concentration		Concentration
Use type	Uses	(%)	Uses	(%)	Uses	(%)	Uses	(%)
		50 distearate		3-8 dicocoate		4 diheptanoate		6 diisostearate
Total/range	24	NR	NR	0.04-0.08	18	0.02-14.3	1	NR
Duration of use								
Leave-on	1	NR	NR	0.04	18	0.02-14.03	NR	NR
Rinse-off	17	NR	NR	0.04-0.08	NR	NR	1	NR
Diluted for (bath) use	6	NR	NR	NR	NR	NR	NR	NR
Exposure type								
Eye area	NR	NR	NR	NR	4	0.4-8	NR	NR
Incidental ingestion	NR	NR	NR	NR	9	0.07-14	NR	NR
Incidental Inhalation-sprays	$1^{a}$	NR	NR	0.04 <sup>a</sup>	2ª; 2°	NR	NR	NR
Incidental inhalation-powders	NR	NR	NR	NR	2°	14.3 <sup>b</sup>	NR	NR
Dermal contact	23	NR	NR	0.04-0.08	9	0.02-14.3	1	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair-noncoloring	1	NR	NR	0.04	NR	NR	NR	NR
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	23	NR	NR	NR	9	0.07-14	1	NR
Baby	NR	NR	NR	NR	NR	NR	NR	NR
	PEG-8	diisostearate	PEG-1	2 diisostearate	PEG-9	0 diisostearate	PEG-1	75 diisostearate
Total/range	12	0.5-4.5	4	2.3-10	11	0.029-2.1	1	5
Duration of use								
Leave-on	5	0.5-2	NR	4	2	2.1	1	NR
Rinse-off	7	1.5-4.5	4	2.3-10	8	0.029	NR	5
Diluted for (bath) use	NR	NR	NR	NR	1	NR	NR	NR
Exposure type								
Eye area	1	4.5	1	NR	NR	NR	NR	NR
Incidental ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-sprays	3°	NR	NR	NR	NR	NR	NR	NR
Incidental inhalation-powders	3°	0.5 <sup>b</sup>	NR	NR	NR	NR	NR	NR
Dermal contact	12	0.5-4.5	4	2.3-10	11	0.029-2.1	1	5
Deodorant (underarm)	NR	2 <sup>d</sup>	NR	NR	2 <sup>a</sup>	2.1 <sup>d</sup>	NR	NR
Hair-noncoloring	NR	NR	NR	4	NR	NR	NR	NR
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	NR	NR	NR	NR	9	NR	NR	NR
Baby	NR	NR	NR	NR	NR	NR	NR	NR

**Table 5.** Frequency and concentration of use of PEG diesters, that have no historical use data, according to duration and exposure.<sup>33,35</sup>

**Table 5.** Frequency and concentration of use of PEG diesters, that have no historical use data, according to duration and exposure.<sup>33,35</sup>

		Maximum		Maximum		Maximum		Maximum
		Concentration		Concentration		Concentration		Concentration
Use type	Uses	(%)	Uses	(%)	Uses	(%)	Uses	(%)
	PE	G-8 dioleate	PEC	G-12 dioleate	NR = Not	Reported; Totals =	Rinse-off	+ Leave-on
Total/range	4	1-5	2	0.024-4.5	Product U	ses.		
Duration of use						ause each ingredie		
Leave-on	2	1	NR	0.024-4.5		iple exposure types		all exposure type
Rinse-off	NR	5	2	0.12-1		not equal the sum t		
Diluted for (bath) use	2	NR	NR	NR	specified	tible these products whether the reported	d uses are s	prays.
Exposure type						sible these products whether the reporte		
Eye area	2	1	NR	NR		ified whether a spr		
Incidental ingestion	NR	NR	NR	NR	possible th	the use can be as a shation is captured in	pray or a po	owder, therefore
Incidental Inhalation-sprays	NR	NR	NR	0.24 <sup>e</sup> ; 0.024 <sup>a</sup>	<sup>d</sup> Not spra <sup>e</sup> Pump ha	у	n bour categ	ones.
Incidental inhalation-powders	NR	NR	NR	0.12-0.15 <sup>b</sup>	i unp na	ii spray		
Dermal contact	2	5	2	0.1-4.5				
Deodorant (underarm)	NR	NR	NR	NR				
Hair-noncoloring	NR	NR	NR	0.024-0.24				
Hair-coloring	NR	NR	NR	NR				
Nail	NR	NR	NR	NR				
Mucous Membrane	2	NR	1	NR				
Baby	NR	NR	NR	NR				

 Table 6. Ingredients not reported to be in current use.<sup>33,35</sup>

PEG-9 distearate	PEG-20 distearate	PEG-32 distearate
PEG-40 distearate	PEG-75 distearate	PEG-190 distearate
PEG-150 dibehenate	PEG-3 dicaprylate/caprate	PEG-4 dicocoate
PEG-2 diisostearate	PEG-3 diisostearate	PEG-4 diisostearate
PEG-2 dilaurate	PEG-6 dilaurate	PEG-12 dilaurate
PEG-16 dilaurate	PEG-20 dilaurate	PEG-32 dilaurate
PEG-75 dilaurate	PEG-150 dilaurate	PEG-2 dioleate
PEG-3 dioleate	PEG-4 dioleate	PEG-6 dioleate
PEG-10 dioleate	PEG-20 dioleate	PEG-32 dioleate
PEG-75 dioleate	PEG-150 dioleate	PEG-3 dipalmitate
PEG-8 ditallate	PEG-12 ditallate	

 Table 7. FDA Code of Federal Regulations that apply to the PEG diesters in this safety assessment.

Use related to food	Ingredients	Code
Can be used for coloring shell eggs if there is no penetration of the shell.	PEG-2 distearate	21CFR73.1
May be used as defoaming agents in food as an emulsifier not to exceed 10% by weight of defoamer formulation.	PEG-8 dioleate; PEG-12 dioleate	21CFR173.340
May be used as indirect food additives: adhesives.	PEG-4 distearate; PEG-6 distearate; PEG-8 distearate; PEG-9 distearate; PEG-12 distearate; PEG-20 distearate; PEG-8 dicocoate; PEG-4 dilaurate; PEG-6 dilaurate; PEG-8 dilaurate; PEG-12 dilaurate; PEG-4 dioleate PEG- 6 dioleate; PEG-8 dioleate; PEG-10 dioleate; PEG-12 dioleate; PEG-8 ditallate; PEG-12 ditallate	21CFR175.105
May be used as paper and paperboard components of paper and paperboard in contact with aqueous and fatty foods.	PEG-8 dioleate; PEG-4 dilaurate	21CFR176.170
May be used as paper and paperboard substances for use only as components of paper and paperboard; components of paper and paperboard in contact with dry food.	PEG-4 dilaurate	21CFR176.180
May be used as paper and paperboard substances for use only as components of paper and paperboard; defoaming agents used in coatings.	PEG-8 dioleate; PEG-4 dilaurate; PEG-12 dioleate	21CFR176.200
May be used as paper and paperboard substances for use only as components of paper and paperboard; defoaming agents used in the manufacture of paper and paperboard.	PEG-4 distearate; PEG-6 distearate; PEG-8 distearate; PEG-12 distearate; PEG-20 distearate; PEG-32 distearate; PEG-8 dicocoate; PEG-2 dilaurate; PEG-4 dilaurate; PEG-6 dilaurate; PEG-8 dilaurate; PEG-12 dilaurate; PEG-20 dilaurate; PEG-4 dioleate; PEG-6dioleate; PEG-8 dioleate; PEG-12 dioleate; PEG-20 dioleate; PEG-32 dioleate; PEG-8 ditallate; PEG-12 ditallate	21CFR176.210
May be used as indirect food additives: polymers. Substances for use as basic components of single and repeated use food contact surfaces; closures with sealing gaskets for food containers.	PEG-8 distearate; PEG-8 dioleate; PEG-8 dicocoate; PEG-8 dilaurate; PEG-8 ditallate	21CFR177.1210
May be used as indirect food additives: polymers. Substances for use as basic components of single and repeated use food contact surfaces; filters, resin- bonded.	PEG-8 distearate; PEG-9 distearate; PEG-12 distearate; PEG-20 distearate; PEG-32 distearate; PEG-8 dicocoate; PEG-8 dilaurate; PEG-12 dilaurate; PEG-20 dilaurate; PEG-32 dilaurate; PEG-8 dioleate; PEG-10 dioleate; PEG-12 dioleate; PEG-20 dioleate; PEG-32 dioleate	21CFR177.2260
May be used as indirect food additives: polymers. Substances for use as basic components of single and repeated use; rubber articles intended for repeated use.	PEG-3 dicaprylate/caprate	21CFR177.2600
May be used as indirect food additives: polymers. Substances for use as basic components of single and repeated use; textiles and textile fibers.	PEG-8 distearate; PEG-9 distearate; PEG-12 distearate; PEG-20 distearate; PEG-32 distearate; PEG-8 dicocoate; PEG-2 dilaurate; PEG-8 dilaurate; PEG-12 dilaurate; PEG-20 dilaurate; PEG-32 dilaurate; PEG-8 dioleate; PEG-12 dioleate; PEG-20 dioleate; PEG-32 dioleate; PEG-8 ditallate; PEG-12 ditallate	21CFR177.2800
Food additives permitted in feed and drinking water of animals.	PEG-8 dioleate	21CFR573.800
Food additives permitted in feed and drinking water of animals: The food additive polyoxyethylene glycol (400) mono- and dioleates may be safely used as an emulsifier in calf-milk replacer formulations.	PEG-8 dioleate	21CFR573.820

Та	able 8. Acute	oral toxicity	studies of PEG-4	4 diheptanoate.

Animal (n)	Results	Comments	Reference
Crl:CD rats (10/sex)	Oral LD <sub>50</sub> was 25 g/kg for	Clinical signs included labored breathing, belly-to-cage posture,	25
	female rats and >25 g/kg for	lacrimation, staining of the face, stained and wet perineal area, and	
	male rats	weight loss. All deaths occurred within 2 days of dosing.	
Wistar rats (5/sex)	Oral LD <sub>50</sub> >2 g/kg	There was no mortality reported. Weight gains were normal in all rats.	42
		Gross pathological examination at necropsy revealed no treatment-	
		related findings. There were no abnormal clinical signs observed except	
		slight piloerection and sporadic findings (eg, ventral or limb position,	
		reduced activity, reduced turgor) up to 6 h after oral administration.	
Male Chr:CD rats (10)	Oral LD <sub>50</sub> >25 g/kg	One mortality occurred on the day after dosing. Clinical signs were	42
		hyperemia, lethargy, and prostration. No systemic toxicity or adverse	
		effects were reported. No gross abnormalities or lesions were observed.	
		Slight initial weight loss was observed. No necropsies were performed.	
Female Crl:CD rats (10)	Oral LD <sub>50</sub> estimated to be 24-25	Test doses: 14, 19, 22, 23, 24, 24.5, 24.75, 24.9 and 25 g/kg in corn oil.	42
	g/kg	Mortalities at each dose level: 0, 0, 0, 0, 4, 1, 2, and 10, respectively. All	
		deaths occurred within 2 days. Clinical signs, observed at all dose	
		levels, included flat body posture, moribund condition, labored	
		breathing, stained/wet perineal area, lacrimation, stained face, weakness,	
		ataxia, lethargy, prostration, salivation and chromodacryorrhea. Body	
		weight decrease was observed at all dose levels. No necropsies were	
		performed.	

	. Genotoxicity assays of PEG-4 diheptanoat	
Assay	Concentration	Results
Bacterial reverse mutation assay using <i>S. typhimurium</i> strains TA98, TA100, TA1535, TA1537	500-10 000 μg/plate, 100-2500 μg/plate (based on toxicity with TA1535). OECD 471 with independent repeat. Positive Control: <i>N</i> -methyl- <i>N</i> -nitro- <i>N</i> -nitroguanidine (TA100 and TA1535 without S9), 9-aminoacridine (TA1537 without S9), 2-nitrofluorene (TA98 without S9) and 2-aminoanthracene (all strains with S9).	Negative with and without metabolic activation
Mammalian cell gene mutation assay using Chinese hamster ovary cells	Without metabolic activation: 0.27-23.9 mM, metabolic activation: 0.25-23.9 mM. 3 independent tests; duplicate cultures/treatment.	Negative with and without metabolic activation

#### REFERENCES

- Nikitakis, J and Breslawec HP. International Cosmetic Ingredient Dictionary and Handbook. 15 ed. Washington, DC: Personal Care Products Council, 2014.
- Andersen, FA. Final safety assessment of PEG-2, -3, -4, -6, -12, -20, -32, -50, -75, -120, -150, and -175 distearate. *International Journal of Toxicology*. 1999;18(Suppl 1):51-59.
- Andersen, FA. Final report on the safety assessment of PEG (polyethylene glycol)-2, -4, -6, -8, -12, -20, -32, -75, and -150 dilaurate; PEG-2, -4, -6, -8, -9, 10, -12, -14, -20, -32, -75, -150, and -200 laurate; and PEG-2 laurate SE. *International Journal of Toxicology*. 2000;19(Suppl 2):29-41.
- Johnson Jr, W, Heldreth, B, Bergfeld, WF, Belsito, DV, Klaassen, CD, Hill, R, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, and Andersen, FA. Final report of the Cometic Ingredient Review Expert Panel on the safety assessment of pelargonic acid (nonanoic acid) and nonanoate esters. *International Journal of Toxicology*. 2011;30(Suppl 3):228S-269S.
- 5. Wenninger, JA and McEwen Jr, GN. International Cosmetic Ingredient Dictionary and Handbook. 7 ed. Washington, DC: Cosmetic, Toiletry, and Fragrance Association, 1997.
- 6. Elder, RL. Final report on the safety assessment of coconut oil, coconut acid, hydrogenated coconut acid, and hydrogenated coconut oil. *Journal of the American College of Toxicology*. 1986;5(3):103-121.
- Burnett, CL, Bergfeld, WF, Belsito, DV, Klaassen, CD, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, and Andersen, FA. Final report on the safety assessment of *Cocos nucifera* (coconut) oil and related ingredients. *International Journal of Toxicology*. 2011;30(Suppl 1):5S-16S.
- Andersen, FA. Annual review of cosmetic ingredient safety assessments 2002/2003. International Journal of Toxicology. 2005;24(Suppl. 1):1-102.
- Andersen, FA. Annual review of cosmetic ingredient safety assessments 2004/2005. International Journal of Toxicology. 2006;26(Suppl. 2):1-89.
- 10. Elder, RL. Final report on the safety assessment of isostearic acid. Journal of the American College of Toxicology. 1983;2(7):61-74.
- 11. Elder, RL. Final report on the safety assessment of oleic acid, lauric acid, palmitic acid, myrisitic acid, and stearic acid. *Journal of the American College of Toxicology*. 1987;6(3):321-401.
- 12. Andersen, FA. Final report on the safety assessment of triethylene glycol and PEG-4. *International Journal of Toxicology*. 2006;25(Suppl 2):121-138.
- 13. Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, DC, Marks Jr, JG, Shank, RC, Snyder, PW, and Andersen, FA. Final report of the Cosmetic Ingredient Review Expert Panel: amended safety assessment of triethylene glycol and polyethylene (PEGs) -4, -6, -7, -8, -9, -10, -12, -14, -16, -18, -20, -32, -33, -40, -45, -55, -60, -75, -80, -90, -100, -135, -150, -180, -200, -220, -240, -350, -400, -450, -500, -800, -2M, -5M, -7M, -9M, -14M, -20M, -23M, -25M, -45M, -65M, -90M, -115M, -160M, and -180M and any PEG >= 4. Washington, DC, Cosmetic Ingredient Review. 2010. pp. 1-49.
- 14. Andersen, FA. Final report on the safety assessment of polyethylene glycols (PEGs) -6, -8, -32, -75, -150, -14M, and -20M. Journal of the American College of Toxicology. 1993;12(5):429-457.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, DC, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Andersen, FA, Burnett, CL, and Fiume, M. Final report: Plant-derived fatty acid oils as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2011. pp. 1-100.
- Elder, RL. Final report on the safety assessment of butyl stearate, cetyl stearate, isobutyl stearate, isocetyl stearate, isopropyl stearate, myristyl stearate, and octyl stearate. *Journal of the American College of Toxicology*. 1985;4(5):107-146.
- 17. Elder, RL. Final report on the safety assessment of PEG-2, -6, -8, -12, -20, -32, -40, -50, -100, and -150 stearates. *Journal of the American College of Toxicology*. 1983;2(7):17-34.
- Robinson, V, Bergfeld, WF, Belsito, DV, Klaassen, CD, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, and Andersen, FA. Amended safety assessment of tall oil acid, sodium tallate, potassium tallate, and ammonium tallate. *International Journal of Toxicology*. 2009;28(Suppl 3):252S-258S.
- 19. Elder, RL. Final report on the safety assessment of steareth-2, -4, -6, -7, -10, -11, -13, -15, and -20. *Journal of the American College of Toxicology*. 1988;7(6):881-910.
- Andersen, FA. Annual Review of cosmetic ingredient safety assessments: 2005/2006. International Journal of Toxicology. 2008;27(Suppl 1):77-142.

- Fiume, M, Heldreth, B, Bergfeld, WF, Belsito, DV, Hill, R, Klaassen, CD, Liebler, D, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, and Andersen, FA. Safety assessment of alkyl PEG ethers as used in cosmetics. *International Journal of Toxicology*. 2012;31(Suppl 2):169S-244S.
- 22. The Pine Chemicals Association, Inc. HPV Task Force. Test plan for tall oil fatty acids and related substances. CAS No. 61790-12-3, CAS No. 65994-03-7, CAS No. 68955-98-6, CAS No. 68201-37-6, CAS no. 61790-44-1, CAS No. 61790-45-2. The Pine Chemicals Association (PCA). 2001. <u>http://www.epa.gov/hpv/pubs/summaries/tofars/c13055tp.pdf</u>. pp. 1-22.
- 23. Budavari, S. The Merk Index. An Encyclopedia of Chemicals, Drugs, and Biologicals. 11 ed. Rahway, NJ: Merck & Co., 1989.
- 24. Nikitakis, JM and McEwen, GN. CTFA Compendium of cosmetic Ingredient Composition-Descriptions II. Washington, DC: Cosmetics, Toiletries, and Frangrances Association, 1990.
- 25. Kennedy Jr, GL. Toxicology of tetraethylene glycol di-n-heptanoate. Drug and Chemical Toxicology. 1985;8(6):409-430.
- O'Neil, MJ, Heckelman, PE, Dobbelaar, PH, Roman, KJ, Kenny, CM, and Karaffa, LS. The Merck Index; An Encyclopedia of Chemicals, Drugs, and Biologicals. 15 ed. Cambridge, UK: Royal Society of Chemistry, 2013.
- 27. McGinty, JW, Hill, JA, and La Via, AL. Influence of peroxide impurities in polyethylene glycols on drug stability. *Journal of Pharmaceutical Sciences*. 1975;64(2):356-357.
- Hamburger, R, Azaz, E, and Donbrow, M. Autoxidation of polyoxyethyleneic non-ionic surfactants and of polyethylene glycols. *Pharmaceutica Acta Helvetiae*. 1975;50(1-2):10-17.
- 29. Robinson, JJ and Ciurczak, EW. Direct gas chromatographic determination of 1,4-dioxane in ethoxylated surfacants. *Journal of Cosmetic Science*. 1980;31(7):329-337.
- 30. Kociba, RJ, McCollister, SB, Park, C, Torkelson, TR, and Gehring, PJ. 1,4-Dioxane. I. Results of a 2-year ingestion study in rats. *Toxicology and Applied Pharmacology*. 1974;30(2):275-286.
- 31. Union Carbide. Triethylene glycol: in vitro genotoxicity studies: CHO/HGPRT mutation test sister chromatid exchange assay.
- Silverstein BD, Furcinitti PS, Cameron WA, Brower JE, and White Jr O. Biological effects summary report polyethylene glycol. NTIS/DE84007984. 1984.
- 33. Food and Drug Administration (FDA). Frequency of use of cosmetic ingredients. FDA Database. 2015. Washington, DC: FDA.
- 34. Food and Drug Administration (FDA). Frequency of use of cosmetic ingredients. FDA Database. Washington, DC: FDA.
- 35. Personal Care Products Council. 10-27-2014. Updated Concentration of Use by FDA Product Category: PEG Di-fatty acids.
- Bremmer HJ, Prud'homme de Lodder LCH, and van Engelen JGM. Cosmetics Fact Sheet: To assess the risks for the consumer; Updated version for ConsExpo 4. 2006. <u>http://www.rivm.nl/bibliotheek/rapporten/320104001.pdf</u>. Date Accessed 8-24-2011. Report No. RIVM 320104001/2006. pp. 1-77.
- 37. Johnsen MA. The Influence of Particle Size. Spray Technology and Marketing. 2004;14(11):24-27.
- Rothe H, Fautz R, Gerber E, Neumann L, Rettinger K, Schuh W, and Gronewold C. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. *Toxicol Lett.* 8-28-2011;205(2):97-104.
- Rothe H. Special aspects of cosmetic spray safety evaluation. 2011. Unpublished information presented to the 26 September CIR Expert Panel. Washington D.C.
- European Commission. CosIng database; following Cosmetic Regulation No. 1223/2009. <u>http://ec.europa.eu/consumers/cosmetics/cosing/</u>. Date Accessed 1-14-0015.
- 41. Casiraghi, A, Di Grigoli, M, Cilurzo, F, Gennari, CGM, Rossoni, G, and Minghetti, P. The influence of the polar head and the hydrophobic chain on the skin penetration enhancement effect of poly(ethylene glycol) derivatives. *AAPS PharSciTech*. 2012;13(1):247-253.
- U.S. Environmental Protection Agency. High Production Volume Information System (HPVIS). http://ofmpub.epa.gov/oppthpv/quicksearch.display?pChem=101113. Date Accessed 10-31-2014.
- 43. Glyco Chemicals, Inc. Properties of various polyethylene and 600, esters of lauric, stearic, and oleic acid.
- 44. Glyco Chemicals, Inc. Properties of various polyethylene and 600, esters of lauric, stearic, and oleic acid.
- 45. Glyco Chemicals, Inc. Properties of various polyethylene and 600, esters of lauric, stearic, and oleic acid.
- 46. Glyco Chemicals, Inc. Properties of various polyethylene and 600, esters of lauric, stearic, and oleic acid.

47. Glyco Chemicals, Inc. Properties of various polyethylene and 600, esters of lauric, stearic, and oleic acid.